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“The saddest aspect of life right now is that science gathers knowledge 
faster than society gathers wisdom.” 
- Isaac Asimov
   
 
 
 ABSTRACT 
 
 
Coronary atherosclerosis is a leading cause of death and disability in the developed world 
and is emerging as such also in developing countries. Despite various efforts, its 
pathophysiology is not fully understood. Atherosclerosis is a chronic, inflammatory, 
lifestyle-disease that is also influenced by genetic factors. Coronary atherosclerosis 
manifests as silent, chronic and acute forms. The acute forms, acute coronary syndromes 
(ACS) are an important cause of death due to coronary atherosclerosis. Clinically, two 
different classes of ACS are distinguished. Depending on electrocardiography, patients 
are divided into those with ST-segment elevation and those without it (STEMI and 
NSTE-ACS, respectively). STEMI and NSTE-ACS differ in mortality, patient population 
and clinical management. 
The major histocompatibility complex (MHC) region is a collection of genes on 
chromosome 6 that are associated with immune response. The genes in this region are 
usually inherited as a strongly linked genetic combination, a haplotype. Certain alleles 
and haplotypes of the MHC region have been linked with coronary atherosclerosis. 
The aims of this Thesis were to develop a novel quantitative polymerase chain reaction 
(qPCR) method for genetic complement component C4 analyses, to confirm the role of 
MHC genes and haplotypes in different clinical forms of ACS and to evaluate the 
possible mechanisms through which the association of MHC genes/haplotypes and ACS 
could be mediated.  
A qPCR method with a novel concentration range approach and SYBR® Green dye was 
developed (I). The method was validated by applying it to over 1600 patient samples with 
available C4 protein data and by analysing 129 samples that were also assessed with other 
methods for C4 gene analysis. Selected MHC genes/alleles (C4 copy number, C4 
mutation, HLA-DRB1*01 and HLA-B*35) were studied in patients with STEMI (III), 
whereas in patients with NSTE-ACS, the C4 variation was studied (II and IV). The 
control population consisted of cases without significant coronary atherosclerosis, a 
general population sample (III) and healthy blood donors (IV). The haplotype frequencies 
were computationally constructed using the Bayesian method. Possible inflammatory 
mechanisms linking MHC and ACS were evaluated by assessing autoantibodies to heat 
shock protein 60 (HSP60, enzyme-linked immunoassay), the level of high-sensitivity C-
reactive protein (hsCRP, immunochemical assay) and by reanalysing the response to 
macrolide treatment in relation to MHC. 
The results indicated that the concentration range and SYBR® Green labelling can be 
used to reliably assess C4 copy number variation and mutation (I). In addition, we found 
that the assessment of C4 mutation can increase the frequency of diagnosed C4 
deficiencies by nearly twenty percentages. 
 The presence of C4 deficiency was not increased in patients with either form of ACS, but 
the power was too low to exclude a weak association (III and IV). DRB1*01 was not 
associated with STEMI, but a haplotype with DRB1*01, with neither C4 deficiency nor 
B*35 was more frequently detected in patients suffering from STEMI than in CAD-free 
controls (III). However, if only men were studied, both DRB1*01 alone and the 
DRB1*01-haplotype were significantly associated with ACS.  
The MHC was shown to associate with alterations in the studied inflammatory 
parameters. C4 deficiency segregated patients that benefitted from macrolide treatment in 
secondary prevention of cardiovascular disease (II). C4 deficiency was also associated 
with elevated HSP60 IgA autoantibody level, which, in turn, was shown to be associated 
with recurrent cardiovascular end points (IV). C4 deficiency was also increased in 
patients suffering from recurrent infections (I). The DRB1*01-haplotype that was 
increased in STEMI associated with higher hsCRP levels in patients and in controls (III).  
In summary, MHC genetics can be assessed by concentration range and SYBR® Green 
labelled qPCR. The MHC region encloses a DRB1*01-related haplotype that associates 
with ACS. The genetic polymorphism in MHC may be linked with ACS by affecting the 
inflammatory responses. These data are observational and thus do not indicate causality. 
However, these data might help to elucidate the complex interplay of inflammatory 
reactions in ACS.
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ABBREVIATIONS 
 
ACS acute coronary syndrome 
C complement component 
C4 complement component 4 
C4A acidic isotype of complement component 4 
C4B basic isotype of complement component 4 
CAD coronary artery disease 
CI confidence interval 
CNV copy number variation 
Cpn Chlamydophila pneumoniae 
CRP C-reactive protein 
Ct threshold cycle 
CTins CT insertion mutation 
DC dendritic cell 
DNA deoxyribonucleic acid 
GWAS genome-wide association study 
HDL high-density lipoprotein 
HLA human leukocyte antigen 
HR hazard ratio 
hsCRP high-sensitivity C-reactive protein 
HSP heat shock protein 
HWE Hardy-Weinberg equilibrium 
Ig immunoglobulin (classes A, G, E and M) 
IHD ischemic heart disease 
IL- interleukin 
LDL low-density lipoprotein particle 
MHC major histocompatibility complex 
MI myocardial infarction 
NSTE-ACS non-ST-elevation acute coronary syndrome 
NSTEMI non-ST-elevation myocardial infarction 
OR odd's ratio 
PCR polymerase chain reaction 
qPCR quantitative polymerase chain reaction 
sHSP soluble heat shock protein 
SLE systemic lupus erythematosus 
SMC smooth muscle cell 
SNP single nucleotide polymorphism 
STEMI ST-segment elevation myocardial infarction 
UAP unstable angina pectoris 
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1. INTRODUCTION 
 
Atherosclerosis is a chronic inflammatory disease that causes significant mortality and 
morbidity worldwide. It affects median-sized arteries of the body. The pathognomonic 
feature of atherosclerosis is the presence of an atheromatous plaque, an atheroma, which 
includes both thickening of the innermost layer of the artery and the formation a soft lipid 
core (“athero” = porridge/paste, “scleros” = hardening in Greek). Coronary artery disease 
(CAD) is a subtype of atherosclerosis, affecting the arteries supplying the heart 1.  
The clinical spectrum of coronary atherosclerosis is wide. Coronary atherosclerosis may 
be silent or manifest as stable cardiac pain on exercise, acute coronary syndrome (ACS), 
rhythm disturbance, heart failure or sudden cardiac death. Whereas coronary 
atherosclerosis is defined as the presence of any atheroma in the coronary vasculature, in 
the clinical use, CAD is denoted as the presence of a significantly large atheroma that 
may cause hemodynamic limitation of blood flow (>50% obstruction). Therefore the term 
“obstructive CAD” is commonly used. A patient with typical symptoms/signs of 
obstructive CAD has ischemic hear disease (IHD). The relationship between IHD and 
obstructive CAD is not straightforward. IHD may sometimes be present independently of 
obstructive CAD and the treatment of obstruction does not necessarily resolve the 
symptoms of IHD 2. Atherosclerotic plaques are estimated to be present in coronary 
arteries in over 70% of population of 16 to 60 years of age 3, whereas the prevalence of 
IHD is less than 15% in Western countries 4, 5.  
In ACS, the atheroma is abruptly disrupted and superimposed by thrombus, leading to 
limitation of blood flow. The mechanisms leading to ACS (a composite of myocardial 
infarction [MI], with apparent tissue necrosis and unstable angina pectoris [UAP], in 
which no necrosis is detected) are not fully understood 6. It has been stated that the 
majority of MI is attributable to modifiable risk factors 7. However, some patients with 
MI present without classical risk factors, whereas some patients with risk factors do not 
develop MI 8, 9, 10,11. The genetic variation 12 and unaccounted environmental factors such 
as infection 13 or autoimmune reactions 14 are factors that may contribute to these 
“unexplained” cases. 
The major histocompatibility complex (MHC) is a gene-rich region in chromosome 6. It 
encompasses over 200 genes that are involved in, e.g., inflammatory reactions 15, 16. 
Genetic variation in the MHC has been linked with various disease conditions 17-19 
including CAD, MI and IHD 20-27. The possible mechanisms of association have not been 
elucidated. 
This Thesis was aimed to develop and validate a novel genetic assay for complement 
component C4 and to confirm the association of four CAD-related MHC genes and 
alleles, HLA-B*35 23, deficiencies of complement component C4A and C4B 21, 28-30 and 
HLA-DRB1*01 23, 31, 32 and their combination in ACS. In addition, the effect of these 
genetic markers on inflammatory level, autoimmune antibodies and on antibiotic response 
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was assessed in order to identify possible pathologic mechanism mediating the 
association between MHC and ACS. 
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2. REVIEW OF THE LITERATURE 
 
2.1 ACUTE CORONARY SYNDROME  (ACS) 
 
ACS is a common cause of mortality and increasing health costs worldwide. It is 
estimated that every 25 seconds, an American suffers a coronary event 5. In Finland, there 
were over 20 000 cases of MI in 2009 (http://www.thl.fi/cvdr). In Finns over 30 years of 
age, 7% of males and 1% of females have survived MI 4.  
 
2.1.1 CLINICAL PRESENTATION  
 
During ACS, the atherosclerotic plaque is disrupted and superimposed by thrombus. This 
leads to acute luminal obstruction of the coronary artery and impaired blood flow to the 
myocardium the vessel supplies. The inadequate supply of oxygen results in ischemia, 
which in turn causes the symptoms, the plaque disruption itself being symptomless. The 
most common symptoms include retrosternal pain, which radiates into left arm, neck, 
jaws or epigastrium. In classical ACS, ischemic pain resembles to that experienced in 
IHD. However, it usually lasts for over 20 minutes. In contrast to IHD, the ischemia may 
result on minimal exercise or even at rest and may be dynamic in nature. The pain may be 
intermittent and accompanied by diaphoresis, nausea, abdominal pain, syncope and 
dyspnoea. The uncommon symptoms include epigastric pain, indigestion, stabbing chest 
pain and pleuritic chest pain. The symptoms may be more varied especially in women, in 
older individuals and in patients with diabetes or heart failure 33, 34. 
ACS involving cardiac cell damage, indicated by release of cardiac biomarkers, is defined 
as MI, whereas in UAP, no significant cardiac cell damage is detected 6, 33. For clinicians, 
the diagnosis of ACS is demanding as the absence of any of the hallmarks of ACS, i.e. 
symptoms, electrocardiographic changes or cardiac biomarker leak does not exclude ACS 
35-37. The symptoms may be so mild that the patient does not know to have suffered from 
ACS. As much as 20% of MIs may go unrecognized 35. Besides coronary atherosclerosis, 
ischemia may also result from other factors such as endothelial dysfunction, embolism 
and anaemia. Depending on the causative agent, five different types of MI have been 
classified (Table 1) 6, 33. Presumably, these classifications may be extended to ACS as 
well. 
The clinical presentation of ACS is not uniform between different patient groups. 
Differences between age groups, ethnicity, gender and socioeconomic status are evident 
in the incidence, presentation, management or outcomes after ACS 7, 38, 39. Women, for 
example, usually present ten years later than men and have increased short-term mortality 
compared with men 39. The mortality rates are decreasing in men, but remain constant in 
young women 38. The risk factor burden seems to associate with a larger risk in men, but 
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hypertension and diabetes seem to be stronger risk factors in women than in men 7, 10. 
However, as women are underrepresented in most studies in CAD, these factors are hard 
to evaluate. 
 
Table 1   
Clinical classification of different types of myocardial infarction 
Type Definition Possible causative agents 
Type 1 Spontaneous infarction due to 
primary coronary event 
Plaque rupture, erosion, fissuring and dissection 
Type 2 Secondary infarction due to 
ischemic imbalance 
Endothelial dysfunction, coronary artery spasm, 
embolism, arrhythmias, anemia, respiratory 
failure, hypotension and hypertension 
Type 3 Cardiac death  
Type 4a PCI  
Type 4b Stent thrombosis  
Type 5 CABG   
Abbreviations; PCI, percutaneous coronary intervention; CABG, coronary bypass by grafting. 
Adapted from Thygesen et al. 33. 
!
 
ACS is associated with high mortality. One estimate states that an American dies of ACS 
every minute 5. Because a significant portion of ACS-related mortality is believed to 
occur before obtaining cardiac markers or electrocardiography, the exact number of ACS-
related mortality cannot be given. According to Finnish data, almost one third of incident 
MI leads to death before reaching a hospital, half within 28 days and a little over half 
within 1 year. However, these figures vary substantially in different age groups and 
gender 40. In some countries, the figures have been reported to be lower 5. In the 
developed countries, the incidence and mortality of MI is declining 38, 40, 41. This trend 
might not continue as only a fraction of adults and adolescent have optimal 
cardiovascular health 42 and less than half of patients with CAD adhere to the medical 
secondary prevention 43. The success of preventive measures in these populations will set 
the future trend on cardiovascular epidemiology. 
Different clinical entities of ACS can be distinguished. Depending on the presence of 
cardiac cell damage, the cases are divided into MI and UAP. Depending on the 
electrocardiographic findings, ACS is divided into cases with prolonged (>20 minutes) 
ST-segment elevation (STE-ACS) and into those without it (non-STE-ACS, i.e. NSTE-
ACS, Figure 1). As most cases with STE-ACS show cardiac cell damage, the ST-
elevation myocardial infarction (STEMI), these terms are interchangeably used. Based on 
cardiac biomarkers, NSTE-ACS is divided into non-ST elevation myocardial infarction 
(NSTEMI) and UAP. At presentation these two entities may not be differentiated from 
each other 6.  
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Figure 1. Classification of acute coronary syndrome. Based on the cardiac 
biomarker leak (for example troponin) and electrocardiography, they are 
grouped into infarctions with or without ST-segment elevation (STEMI and 
NSTEMI) or unstable angina pectoris. Adapted from Hamm et al. and Nikus et 
al. 34, 44 
 
In the clinical use, the most important distinction is made between STEMI and NSTE-
ACS. STEMI is though to associate with complete occlusion of a coronary artery. It is 
less common than NSTE-ACS and is more often treated invasively due to the higher early 
mortality rate 6. The invasive treatments include percutaneous coronary intervention and 
coronary artery bypass by grafting. Patients with STEMI are usually younger, have less 
comorbidity and are more often males than patients with NSTEMI 45. Currently, the 
relative rate of STEMI is declining, whereas the relative incidence of NSTEMI is 
increasing 45. These changes are due to changes in the definition of MI, decreased 
incidence and mortality 36, 38, 40, 46. The population trends in the incidence of UAP are 
controversial 38. 
At the local level, the underlying difference between STEMI and NSTE-ACS is the 
duration and the extent of the coronary artery occlusion (Figure 2). However, this view is 
simplistic as various factors in oxygen content, coronary anatomy, coronary blood flow 
and coronary blood demand, modulate the clinical picture of ACS (Table 1). Plaque 
rupture (70 vs. 47%), thin-cap atheroma and red thrombus are more often detected in 
STEMI than in NSTE-ACS 47. The site of plaque rupture (pre- vs. post-stenosis) may also 
vary between STEMI and NSTE-ACS 47.  
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Figure 2. Acute coronary syndromes. Plaque rupture or erosion may lead to total occlusion of the 
coronary artery, usually causing STEMI (A). However, in the presence of collateral circulation or 
spontaneous thrombolysis, the electrocardiography may correspond to NSTEMI or UAP. If the 
occlusion by thrombus is partial and possibly accompanied by distal embolization, the resulting 
clinical picture is most often NSTEMI or UAP (B). 
 
 
2.1.2 PATHOPHYSIOLOGY 
 
2.1.2.1 Pathophysiology of coronary atherosclerosis 
 
Even though the first observations linking inflammation with atherosclerosis were 
published in the beginning of the 19th century, the two scientists that published their work 
in the mid-19th century, Carl Rokitansky and Rudolph Virchow are usually accounted for 
discovering the inflammatory nature of atherosclerosis. Rokitansky suggested that the 
initiating step of atherosclerosis was caused by the accumulation of blood-derived 
products in the arterial wall, and inflammation was the reaction to the accumulated lipids. 
Rudolph Virchow, in turn, suggested that the inflammatory reactions were the 
preliminary step. After these researchers, inflammation in atherosclerosis was forgotten 
for almost one hundred years 48. In the 1970’s, three prevailing viewing points, 
endothelial injury, smooth muscle cell (SMC) growth and the lipid hypothesis were 
combined under the “response to injury” hypothesis by Russell Ross 49.  Evolving from 
this hypothesis, atherosclerosis is currently seen as an inflammatory disease including 
various cell types and lipoprotein metabolism, which is affected by genes and risk factors 
(such as aging, smoking, diabetes mellitus, hypertension, dyslipidaemia and family 
history of early CAD [MI before 55 years of age in males or before 65 years of age in 
females]). Although the inflammatory reactions are accepted to be involved in all stages 
of atherosclerosis progression, the debate on the initiating step is still on-going 50.  
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An atherosclerotic plaque may present as uni- or multifocal changes in an individual. It is 
usually found in predicted locations, predominantly in the proximal portions and in the 
branching points of the arteries. The atherosclerotic plaque forms in the innermost, 
intimal layer of arteries through various stages during several years or even decades. The 
possible causative/initiating elements are altered lipoprotein particles, cholesterol crystals 
and endothelial injury 51-53.  
The earliest stage of atherosclerosis is called the fatty streak, where cholesterol is 
accumulated within inflammatory cells, the foam cells. It is formed when blood-derived 
lipoprotein particles are retained in the intima, undergo biochemical modification and are 
subsequently internalized by macrophages. The following step is the formation of a 
fibrofatty atheroma, which includes a necrotic core of extracellular lipids and dead cells 
underneath a fibrous cap. It is formed by amplification of local inflammation, recruitment 
of inflammatory cells and SMCs, death of foam cells and accumulation of lipid-rich core. 
The last stage, the complicated atheroma has features of neovascularization, repeated 
injury, growth, calcification and remodelling (Figure 3) 6.  
 
 
 
Figure 3. Simplified presentation of the formation of an atheroma. A fatty streak is present in 
young individuals and consists mainly of macrophages, T-cells and lipoprotein particles 
(cholesterol). A fibrofatty atheroma is formed when a lipid-, cholesterol crystal- and cellular 
debris- containing necrotic core is detectable under a fibrous cap consisting of smooth muscle cells 
and extracellular matrix. The complicated atheroma continues to grow due to inflammation, 
intraplaque hemorrhage from infiltrating microvessels (neovascularization), and plaque erosion 
and rupture. The atheroma undergoes dynamic changes in size of the lipid core, thickness of the 
fibrous cap or in the level of internal or external remodelling (growth inwards or outwards) 50, 54.  
 
Almost all inflammatory cell types have been identified in atherosclerotic plaques. The 
most important cells are monocytes/macrophages, T-cells, neutrophils, mast cells, 
dendritic cells (DCs) and B-cells. The cellular subtypes may exhibit important variations 
in mediating either proatherogenic or atheroprotective effects. For example, regulatory T-
cells, B-1-cells and myeloid DCs have been stated to depress atherosclerotic changes, 
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whereas CD8+T-cells, plasmocytic DCs and B-2-cells cause progression of an 
atherosclerotic plaque 52, 53, 55. The role of inflammatory cells residing outside the plaque, 
in the adventitia and/or perivascular adipose tissue, are also gaining interest 56. Various 
cytokines, produced mainly by T-cells and macrophages have been identified as pro-
atherogenic (interleukin [IL-] 1, 2 and 18, macrophage colony-stimulating factor, tumor 
necrosis factor alpha and interferon gamma) as anti-atherogenic (IL-10) or as having dual 
function (IL-4, IL-6, granulocyte macrophage colony-stimulating factor) 57. Complement 
components are present in the plaque in a spatial fashion. The inner intima harbours 
classical and alternative pathway components, whereas the deeper layers harbour also the 
end product, the membrane-attack complex 58. Other blood-derived molecules such as 
immunoglobulins (Igs), C-reactive protein (CRP) and hemosiderin may be present in the 
atheroma as well 52, 53, 55. 
 
2.1.2.2 Pathophysiology of ACS 
 
ACS is one of the possible outcomes of an atherosclerotic plaque (Figure 4). 
Atherosclerosis and superimposing thrombus, atherotrombosis, causes the majority of 
ACS, although other causes, both due to atherosclerosis and independent of it, have also 
been identified (Table 1). In atherothrombosis, the atherosclerotic plaque is either 
ruptured, where the fibrous cap is partly absent and the lipid core and vascular wall 
become in contact with blood. As these structures are very prothrombotic, a 
superimposing thrombus is formed. Another cause of atherothrombosis is the superficial 
erosion of the atheroma, where the fibrous cap is still intact, but the endothelial/intimal 
structure is damaged (Table 2) 6. The third cause, the calcified nodule has also been 
suggested, but data regarding it is scarce and it may be more important in the carotid 
atherosclerosis 59. Atherothrombosis may instantly cause ACS, but in some cases, the 
ischemic symptoms develop several days after the thrombus formation 60. 
Atherothrombosis does not always lead to ACS but may result in plaque growth (Figures 
2 and 4) 61.  
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Figure 4. A proposition for the natural history of atheromatous plaques. Regression until type 
III is possible, but after this point, at the formation of a lipid core, the atherosclerotic plaque 
is formed and may lead to different plaque types (V–VIII). Surface disruption or erosion, 
hemorrhage and/or thrombosis (VI) may result in plaque growth or acute coronary syndromes 
(ACS). Modified from Stary 62. 
 
Table 2     
Rupture, erosion and calcified nodule in different forms of ACS and CAD 
Clinical presentation Rupture Erosion Nodule Reference 
Sudden cardiac death 55–60% 30–35% 2–7% 59
 
MI 73 % 23 % . 63
 
STEMI 70 % . . 47
 
NSTE–ACS 47 % . . 47
 
Stable CAD 27 % . . 64
 
 “.” stands for not reported. 
 
In lack of animal models for spontaneous plaque rupture and erosion, the current 
knowledge on local cellular and molecular mechanisms leading to ACS are based on 
human histopathology findings 52. The plaque characteristics associated with plaque 
rupture have conventionally been called as features of “vulnerable plaque”, although a 
vulnerable plaque, a plaque that is prone to cause ACS, in its true sense, should also cover 
characteristics of plaque erosion. The plaque characteristics that are associated with 
rupture are a thin fibrous cap, large lipid core and an abundance of macrophages within 
the cap, low number of SMC, intraplaque haemorrhage, spotty plaque calcification, large 
plaque size and external remodelling 59, 65, 66. Various markers of inflammation, including 
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serum high-sensitivity C-reactive protein (hsCRP), associate with the aforementioned 
plaque characteristics 65. 
The plaque characteristics associated with erosion are calcification, eccentric, 
pathological intimal thickening and fibrous cap atheroma. In plaque erosion, there is 
minimal inflammation, and most often the necrotic core is minimal. As erosion is less 
common and is linked with several plaque characteristics, the data concerning the 
pathophysiology of erosion is scarce. Extracellular matrix composition, coronary 
vasospasm and myeloperoxidase are linked with coronary plaque erosion 54, 59, 67, 68.  
The initiating factor for plaque disruption (erosion or rupture) is not known. Various 
internal, external, systemic and local factors that are associated with ACS have been 
described, but it is not known, how specific they are to ACS instead of being mere 
markers for CAD. The most probable mechanism of ACS is a network of various factors 
that converge in thrombosis-prone and/or rupture-prone state, which, when occurring 
simultaneously, may result in ACS (Figure 5). 
 
 
 
Figure 5. An example of a network of factors affecting the risk of ACS. Adapted from Arbab-
Zadeh et al. 68. Note that genetic variation might influence the presence of a certain risk factor of 
the relationship/effect of different risk factors.  
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2.1.3 GENETICS 
 
The research focusing on ACS is extensive. Its particular challenges are the recent change 
in the definition of MI, rending the comparisons between old and new data problematic 
and the difficulty of clinical diagnosis of ACS, possibly omitting certain patient groups 
(the elderly, women and patients with UAP) from clinical studies. Currently, the majority 
of research involves only men, patients with MI (not UAP) and of cases of European 
descent. 
The genetic factors are important in the pathogenesis of CAD/ACS. Family history of 
premature MI is a risk factor for IHD and MI 69, 70. In addition, family history of any MI 
(all MI and non-premature MI) is also a risk factor for MI, although the risk is generally 
lower 7, 69, 70. This increased risk may be attributed to shared environmental factors such 
as unhealthy health habits, shared genetic factors that lead to ACS or shared genetic 
factors that affect the risk factor prevalence and thus affect ACS intermediately 71, 72. 
However, epidemiological data has shown that family history of MI is independent of 
traditional risk factors 7, 69, 70, 73. Furthermore, a recent adoption study showed that genes 
transmit a stronger risk for CAD than the shared environment does 12. Also supporting the 
role of genetic contribution of ACS, a large twin study showed that heritability (h2) of 
death due to CAD is 0.38 (95% confidence interval [CI]=0.26–0.50) for women and 0.57 
(95%CI=0.45–0.69) for men. In addition, in men, the risk attribution for monozygotic 
twins was significantly higher than for dizygotic twins 74. However, the heritability of 
CAD can vary between different phenotypes, age and ethnicity 75, 76.  
Candidate gene studies have associated polymorphism of various genes with CAD/MI. 
However, these results have not been reliably replicated. The known candidate genes 
encompass mainly genes within pathways that are involved in the pathogenesis of 
CAD/MI, such as lipoprotein metabolism, risk factors and inflammatory processes 77.  
Following the somewhat disappointing results of candidate gene studies, the results of 
genome-wide association studies (GWAS) were much anticipated. These studies were 
based on testing as many as one million single nucleotide polymorphisms (SNPs) 
simultaneously and comparing these between cases and controls. Since 2007, the 
hypothesis-free GWAS have confirmed at least 46 SNPs that associate with CAD/MI. 
These SNP associations remain enigmatic because they are usually present in non-coding 
sequences, cause relatively low risk addition, are frequently found in healthy populations, 
have pleiotropic effects with other conditions besides CAD/MI and most often do not 
form any known network of protein-protein interaction, co-expression network or 
biological pathway. The known risk SNPs attribute only for 6% of estimated heritability 
(0.4) for CAD. In the future, novel strategies in the genetic research are warranted 77-80. 
The major histocompatibility complex (MHC) region on chromosome 6 includes genes 
that affect the immune responses and host defence. The genetic variation in this region is 
extensive and consequently, the earlier SNP assays did not cover this region in sufficient 
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detail 17. Denser MHC-coverage has now been obtained and there is increasing evidence 
linking the MHC region with CAD/ACS both in GWAS and candidate gene studies, 
emphasising the role of inflammation in CAD/ACS (See Section 2.2.1). 
Most genetic studies have been conducted with a combination of CAD and MI. Lately, 
concern was raised that the genetic background is different in these conditions 81. 
However, a replication study could not confirm that different clinical manifestations were 
more strongly associated with different phenotypes, but the power to discriminate 
between different phenotypes was low 82. It has been suggested that the majority of CAD-
related genes increase the likelihood of CAD and thereby, indirectly the risk of ACS 75.  
 
 
2.1.4 PREDICTION 
 
Currently, the prediction ACS by plaque characteristics 83, genetic risk score 84-87 or 
biomarkers 88 do not add significantly to the standard risk assessment of traditional risk 
factors or algorithms done by SCORE, FINRISK, Framingham risk score in the general 
population. However, these unconventional strategies might be useful in patients with low 
or moderate risk 89.  Given the imperfect predictive value of classical risk factors 8, 9, 10,11 
there is an impelling need for understanding the pathophysiologic event that results in 
CAD and ACS. This knowledge would help to better identify high-risk patients and 
hopefully lead to the development of novel pharmacotherapeutic approaches. 
In the future, the so-called -omics (genomics, metabolomics, proteomics) and systems 
biology approaches are expected to enlighten the pathophysiology of CAD and ACS. The 
improved imaging modalities will hopefully help to determine the natural history of the 
atherosclerotic plaque. The prevention of CAD might be targeted to the prevention of risk 
factor emergence, through the “primordial prevention”. Novel therapeutic approaches 
include stem cell therapies, new treatment devices, deoxyribonucleic acid (DNA) 
targeting, pharmacogenomics and personalized medicine 90. Various different treatment 
strategies against inflammatory reactions are also under way (see Section 2.3.1).
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2.2 THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) 
 
The MHC region was discovered in the 1950’s. It was named for being the major cluster 
of genes controlling the allograft outcome after transplantation. The MHC region is 
located in chromosome 6 (6p21.3) and it contains over 220 genes. It is divided into three 
classes from I to III (Figure 6). The surrounding genome is rather conserved and it, 
together with the MHC region, is denoted as the extended MHC. The extended MHC 
covers over 420 genes. The MHC region is extremely rich in polymorphism (number of 
different alleles), has strong linkage disequilibrium, which may differ in length between 
regions, alleles, and populations 17. The MHC region has been linked with over 100 
autoimmune, infectious and inflammatory diseases. Until lately, GWAS did not often 
sufficiently cover the MHC region, but new methods do so into much greater detail. In 
humans, MHC classes I and II are called the human leukocyte antigen (HLA). 
Throughout the Thesis, this nomenclature is applied.  
 
 
Figure 6. Simplified presentation of the organization of the MHC region. The class II MHC 
genes encode for both ! and " subunits of classical HLA II molecules HLA-DP, -DQ and –DR 
(DPA and DPB, DQA and DQB, DRA and DRB for ! and " subunits, respectively). In addition 
to the protein-coding genes, various pseudogenes are also present. Class III MHC is a 
collection of non-related genes between classes I and II. The class I MHC harbors the genes 
encoding for the ! subunit of classical HLA I molecules HLA-A, -B and -C. For detailed 
structure of C4 gene region, see Figure 11. Based on Marsh et al. 91. 
 
Immune reactions against foreign HLA I and II molecules are still amongst the major 
determinants of transplant outcome. These reactions include both humoral and cellular 
immune reactions. It is currently not known how big a mismatch is safe for 
transplantations. It seems that the organ in question as well as the type of transplantation 
(solid organ vs. blood marrow) affect the rate of acceptable mismatches. Autoantibodies 
to non-self HLA may arise from multiple pregnancies or blood transfusions 92. 
The nomenclature in the HLA is somewhat complex. Different HLA alleles are 
numerically separated, whereas colons separate the different information about the 
!"#$$%&&% !"#$$%&&&% !"#$$%&%
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structure. The first numbers group all alleles with a given allele family, corresponding to 
the old serological groups. The second numbers gather the alleles differing in their amino 
acid sequence. The third numbers differentiate alleles having synonymous mutations and 
the last digits segregate nucleotide changes in introns or in the untranslated regions 
(Figure 7) 93. 
 
 
 
Figure  7. Nomenclature and classification of HLA-alleles, with DRB1*01 as an example. Based on Robinson 93. 
 
 
 
 
2.2.1 MHC GENES IN CORONARY ARTERY DISEASE (CAD) 
 
Many studies have identified both susceptible and protective factors for CAD in the 
MHC. Lymphotoxin alpha SNPs, complement component C4 deficiency and 
DRB1*01 allele are amongst the most studied factors in the MHC (Table 3). In 
addition, the MHC region has been also linked with blood lipids 94, large-artery 
atherosclerosis 95 and cardiovascular mortality in patients with autoimmune 
conditions 96, 97 98, 99. The MHC region may also be linked with endothelial 
dysfunction 100. 
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Table 3    
Recent studies reporting MHC genes in CAD     
  Phenotype Comment Reference 
Genome-wide association studies    
HLA II SNP CAD/MI Susceptible 27
 
HLA I SNP CAD/MI Meta-analysis, susceptible 26 
HLA II SNP MI Susceptible 101
 
Candidate gene studies   
 HLA-G SNPs CAD Susceptible 25 
LTA (TNF-B) SNPs CAD/MI Conflicting data 23, 27, 30, 102, 103 
TNF-! (308A) SNP CAD/MI Conflicting data 104
 
Factor B CAD No association 28
 
C4 deficiency CAD Conflicting data See Table 10 
C2 deficiency MI Complete deficiency 105
 
HSP70 SNP CAD/MI/IHD Susceptible 24
 
HFE SNP CAD/MI Conflicting data 106
 
HLA I and/or II alleles screened   
 HLA-DRB1*01 CAD Susceptible See Table 7 
HLA-DRB1*04 CAD Susceptible 32
 
HLA-B Premature MI Susceptible 20
 
HLA-DRB1*15 CAD/MI Protective 23
 
DRB1*07 MI Protective 31 
HLA-DRB1*12:02:01 CAD Protective 107
 
HLA-haplotypes   
 DRB1*01-B*35 CAD/MI Susceptible 23 
DRB1*07-DQA1*02-DQB1*02 MI Protective 31
 
DRB1*0101-DQA1*01-DQB1*05 MI Susceptible 31
 
Abbreviations; SNP, single nucleotide polymorphism; LTA, lymphotoxin alpha; TNF, tumor necrosis factor; HSP, heat 
shock protein; HFE, high serum Fe, for hemochromatosis. 
 
2.2.2 MHC I 
 
HLA I molecules are formed from two subunits, the ! chain (aka. the heavy chain) and 
the "2-microglobulin (Figure 8). Class I HLA genes encode for the ! chain, whereas "2-
microglobulin is encoded in chromosome 15. The classical HLA I (aka. class Ia) gene 
products are components of HLA-A, -B and -C. In addition to these, the class I MHC 
region harbors also non-classical HLA I-genes (HLA-E, HLA-F and HLA-G), 
pseudogenes (HLA-J, -K, -L), structurally HLA I-like genes (hemochromatosis and MHC 
class I chain-related genes A and B) and approximately 50 additional genes that are not 
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related in form of function with HLA I or II. The remaining HLA-like proteins (for 
example CD1) are encoded in other regions of the genome 91. 
 
 
Figure 8. HLA I and II molecules. The subunits 1–3 in ! chain of MHC I 
correspond to exons 2–4 encoded in HLA I, and "2 is for B2-microglobulin.The 
subunits 1–2 in MHC II correspond to exons 2 and 3 in either A or B gene, both 
in the HLA II. The peptide fragments are anchored within the peptide-binding 
groove by peptide-binding pockets, of which there are six on HLA I and five on 
HLA II. Each pocket is formed from various amino acid residues on the HLA 
molecule 91. 
 
The HLA I molecules are cell-surface glycoproteins present in all nucleated cells. The 
classical HLA I molecules activate CD8+ killer T-cells through the interaction of peptide-
HLA I complex, costimulatory molecules and the !" T-cell receptor. This enables the 
screening of cellular function (protein synthesis), leading to killing of infected or altered 
cells by the CD8+ killer T-cells 91. Certain HLA I molecules inactivate natural killer cells 
through killer immunoglobulin-like receptor (namely the HLA-A, -B and C) and 
CD94/NKG2A receptor (HLA-E) 108. The HLA I molecules may affect antigen-
presenting cell function by interacting with the inhibitory leukocyte immunoglobulin-like 
receptor as well 109.  
The HLA I molecules present mainly peptides derived from the intracellular 
compartment. Peptides from extracellular proteins can be presented in HLA I by cross-
presentation and possibly also by acquiring membranes directly from other cells 110. In 
addition, soluble HLA I molecules circulating in blood are stable, increase in 
inflammatory diseases and may have immunoregulatory functions 111. Non-
immunological functions such as neuronal development have recently been described for 
HLA I molecules 112.  
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Over 5000 HLA class I alleles have been identified 93. The majority of the allelic 
variation resides in exons 2 and 3, leading to amino acid polymorphisms in the peptide-
binding region between !1 and !2 subunits and possibly affecting the selection of peptides 
presented to CD8+ T-cells (Figure 8). The peptide repertoire of certain HLA I allele is 
becoming unraveled and is very polymorphic, tissue specific, affected by the presence of 
different proteases and surprisingly restricted. Factors such as medication, infection, 
metabolic changes and cancer affect the peptide repertoire 113, 114.  
 
2.2.2.1 HLA-B*35 
 
At least 205 different B*35 alleles coding for different proteins have been described 93. 
The frequency of B*35 varies amongst different geographical areas, even within Finland 
115. B*35 is a part of ancestral haplotype 35.2, a collection of HLA-genes that are usually 
inherited together and often seen in different populations. Besides B*35, the 35.2 
ancestral haplotype includes A*03, C*04, C4B null allele, DRB1*01:01 and DQB*05:01 
116. A haplotype otherwise like the 35.2, but including A*11 has also been described 117. 
B*35 has been associated with infectious and autoimmune conditions (Table 4). Other 
HLA-alleles have also been associated with these conditions and no definite conclusions 
on B*35 in disease pathology have yet been made. In addition, B*35 has been involved in 
increased apoptotic signaling 118 and altered endothelial cell function 119. B*35 has been 
associated with CAD only as a part of haplotype together with a HLA II allele DRB1*01 
23. 
 
Table 4   
Recent disease associations of HLA-B*35  
Condition Association Reference 
Infections   
HIV Accelerated progression 120-122 
Chlamydophila pneumoniae Positive serology 123
 
Hepatitis B Positive surface antigen 124
 
Hepatitis C Chronic infection 125
 
   Autoimmune/inflammatory   
Pulmonary hypertension  In patients with systemic sclerosis 126
 
Presentation of leprosy Association with tuberculoid form 127
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2.2.3 MHC II 
 
The HLA II molecules are cell-surface glycoproteins formed from non-covalent joining 
of ! and " chains, encoded by corresponding HLA II genes (for example HLA-DRA and 
HLA-DRB, for ! and " chains, respectively). In contrast to HLA I, HLA II molecules are 
entirely encoded by the MHC region and the peptide-binding pocket is determined by 
both ! and " chains (Figure 8). Classical HLA II-molecules (HLA-DR, -DQ and -DP) are 
involved in T-cell activation, whereas the non-classic molecules (HLA-DM and -DO) are 
participating in intracellular MHC II assembly. Other genes in MHC II region are mainly 
involved in the function of HLA I molecules (transporter associated with antigen 
processing) 91.  
The genetic polymorphism is the most prevalent in the peptide-binding pocket and 
promoter region, but for HLA-DRA, the gene coding for ! chain is largely invariant. 
HLA- DR " chain is encoded by HLA-DRB1, -3, -4 and -5 genes, all of which have 
allelic variation. HLA-DR genes can be divided into haplogroups that vary in the 
presence of additional DRB genes and pseudogenes (Table 5). As a result, humans may 
have from one to four different HLA-DR molecules on their cellular surface 15, 91.  
HLA II molecules are present on professional antigen-presenting cells, including DCs, 
monocytes, macrophages and B-cells. Upon stimulation, various other cell types such as 
endothelial cells, SMCs and T-cells. Usually, HLA II molecules present peptides from 
extracellular origin, but in some cases, also intracellular peptides are presented. The best-
known function of HLA II is the activation of T-cell receptors on helper CD4+ T-cells. 
HLA I and II molecules are also involved in T-cell priming and selection in thymus 15, 16.  
 
Table 5 
     
Major HLA-DR haplogroups 
Haplogroup DRB gene DRB1 alleles Pseudogene 
Additional 
DRB 
Pseudogene 
DR1 DRB1 *01, *10 DRB6 
 
DRB9 
DR8 DRB1 *08 
  
DRB9 
DR51 DRB1 *15, *16 DRB6 DRB5 DRB9 
DR52 DRB1 
*03, *11, *12, 
*13, *14 
DRB2 DRB3 DRB9 
DR53 DRB1 *04, *07, *09 DRB7 DRB4 DRB9 
Adapted from Handunnethi et al. 128. 
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The role of HLA II molecules beyond T-cell activation is largely unknown, but HLA II 
has also been associated with intracellular cross-talk with Toll-like receptor-signaling 129 
and regulatory signal transduction/receptor function130,131. The role of HLA II molecules 
on non-antigen-presenting cells are not understood, but they might be take part in 
attenuation of inflammatory reactions 132 or promotion of T-cell activation 133. In addition 
to the membrane-bound HLA II, soluble HLA II molecules are detected in blood and 
other body fluids 134. Soluble HLA II may be elevated in disease conditions 133, 135, 136 and 
possibly elicit or enhance T-cell activation 137. The expression of HLA II molecules is 
tightly regulated and includes chromatin modification, cis- and trans-acting regulatory 
elements and long-range controlling 138, 139. 
 
2.2.3.1 HLA-DRB1*01 
 
HLA-DRB1*01 is one of the 16 allele groups of the DRB1 gene. DRB1*01 is divided into 
49 different protein-coding alleles (DRB1*01:01-DRB1*01:49), which, in turn are 
divided into 30 alleles, differing by exon sequence, but not by amino acid structure 
(Figure 7) 93. DRB1*01 is more frequent in Europe and Eastern Asia than in other 
geographical areas. In worldwide populations, the frequency of DRB1*01 ranges from 0 
to 0.24. Of the protein-coding allele groups, DRB1*01:01 and *01:02 are the most 
common. In Finland, the most common protein-coding allele is DRB1*01:01, covering 
half of the DRB1*01 140. In Swedish population, the frequency of DRB1*01:01 is almost 
two times higher than the frequency of DRB1*01:02 31. Our recent data suggests that the 
proportion of DRB1*01:01 in Finland might be significantly higher than reported earlier 
(Eronen et al, unpublished data). The frequency of DRB1*01:01 also varies by 
geographical area, ranging from 0 to 0.19. The highest frequency is found in Eastern 
Europe. For DRB1*01:02, the frequencies range from 0 to 0.12, being the highest in 
Africa. The DRB1*01:01 allele can be divided into 22 subtypes having synonymous 
mutations 140.  
DRB1*01 has been linked with various inflammatory and infectious conditions, but most 
of these associations have also been described for other HLA-alleles as well. Overall, the 
associations are not very strong and they are not DRB1*01-specific. These associations 
usually cover autoimmune conditions and viral infections, both susceptibility to 
symptomatic infection and resistance (Table 6).  
The most studied disease association of DRB1*01 is its association together with some 
subtypes of DRB1*04 and DRB1*10 with rheumatoid arthritis. These alleles are 
collectively called the “shared epitope” alleles for their sequence similarity. It has been 
suggested that interaction with smoking, serotonin receptors, activation of cell surface 
molecules independent of the presented peptide or the distinctive structure on the rim of 
DRB molecule mediate the possible effect, but causality has not been shown between the 
shared epitope alleles and rheumatoid arthritis 141-143. 
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Table 6   
Recent reported disease associations of HLA-DRB1*01   
 Association Reference 
Infection   
Sindbis virus Associated with symptomatic infection 144
 
Human immunodeficiency virus Associated with resistance 145
 
Hepatitis C Associated with increased viral clearance 146
 
Recurrent lymphocytic meningitis Association 147
 
Periodontitis Association  148
 
Ebstein-Barr virus Associated with symptomatic infection 149
 
Inflammation   
Rheumatoid arthritis Association  150
 
Juvenile idiopathic arthritis Association  151
 
Autoimmune hepatitis Association  152  
Henoch-Schönlein purpura Association 153
 
Other   
Coronary artery disease Association See Table 6 
Chagas disease Protective from complications 154
 
Allergy Mugwort pollen and cockroach  155, 156 
Lung cancer Death to lung cancer in patients with 
rheumatoid arthritis 
97 
Hypersensitivity Hypersensitivity to nevirapine 157, 158 
Non–Hodgin lymphoma Association 159
 
 
 
There are various peptides that have been shown to bind to DRB1*01:01 in either 
peptide-binding assays or from naturally presented peptides enlisted in the immune 
epitope database (www.immuneepitope.org). There are at least 45 peptides have been 
eluted from tissue DRB1*01, but these data or based on two individuals or on cell 
cultures 160, 161. The eluted peptides include apolipoprotein E and B, tubulin and 
transferrin receptor. For DRB1*01:02, only cell line eluates has been characterized 160. 
These eluates included mosty different peptide fragments between DRB1*01:01 and 
*01:02, although some overlap was detected. 
 
2.2.3.2 DRB1*01 in CAD 
 
DRB1*01 has been linked with different forms of CAD/MI in four independent materials 
and three different ethnic groups with odd’s ratios (ORs) from 1.2 to 4.7 (Table 7). In 
three populations, no association was found, but these studies were performed in either in 
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populations with low DRB1*01 frequency in the general population 107 or with small 
sample size 162. Other MHC genes have also been linked with CAD (see Section 2.2.1) 
 
Table 7       
Studies assessing DRB1*01 in CAD   
  Frequencya Na Phenotype OR Population Reference 
Association       
*01:01 0.09/0.07 1188/1191 MI 1.24 (1.00–1.53) Swedish 31
 
*01 0.22/0.07 166/150 CAD/MI/IHD 4.71 (not reported) Chinese 32
 
*01 0.21/0.10 100/74 NSTE-ACS 2.36 (1.25–4.44) Finnish 23
 
1 0.13/0.07 115/90 CAD 2.37 (1.33–4.25) Finnish 23
 
No association      
1 0.16/0.15 50/50 CAD  Swedish 162
 
1 0.14/0.08 50/48 premature CAD  Swedish 162
 
*01:01:01 0.009/0.00 219/208 CAD  Chinese 107
 
*01:01:02 0.002/0.00 219/208 CAD   Chinese 107
 
a cases/controls. 
 
2.2.4 COMPLEMENT COMPONENT C4 
 
Class III MHC is a gene rich region between MHC I and II that harbors at least 75 genes, 
35 of which are expressed (Figure 6) 163. The C4 protein is first synthesized as a single-
chain pre-protein, which undergoes cleavage into three subunits as well as biochemical 
modifications including glycosylation and sulfation. After secretion, this molecule is 
further cleaved. The biochemical modifications are not uniform, leading to the presence 
of different C4 molecules in plasma. The presence of various protein forms is the reason 
for pre-treating C4 proteins by neuraminidase and carboxyl peptidase B and thus reducing 
the protein variation prior to immunophenotyping (Figure 9) 164. C4 is secreted by 
various cell types including macrophages, fibroblasts and activated platelets, but liver is 
the major source of serum C4 protein 165, 166. The serum levels of total C4 vary from 0.13 
to 0.54 (g/L) depending on age, body mass index, C4 gene number, surrounding genes, 
consumption, gene length and circadian rhythm 167 168-171. The surrounding HLA region 
may also affect the C4 level, but the extent to which the surrounding HLA modulates the 
effect of C4 copy number variation (CNV) is not known 172. C4 may be differentially 
expressed in different inflammatory cell subsets 173. C4b binds to complement receptor 1 
on blood cells, B-cells, DCs and monocytes and functions as an opsonin. The other 
function of C4b is the formation of C3 convertase together with C2, ultimately leading to 
membrane-attack complex formation164. Complement C4 is a part of classical and lectin 
complement activation pathways although a C4-independent activation route in lectin 
pathway has been described (Figure 10).  
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Figure 9. A simplified schematic presentation of the complement component C4. The protein is 
formed from three peptide chains, !, " and #. These subunits are linked through disulphide bonds 
(lines). One of the most important structures of C4 is the internal thioester bond (the lightning 
symbol), located in the ! chain. The anaphylatoxin cleaved from C4 is also located in the ! chain 
(dark box on the left end of ! chain). The amino acid variation leading to the different allotypes 
(C4A and C4B protein isoforms) is located near to the thioester bond region. Modified from 
Atkinson and Yu 164. 
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Figure 10. Complement component C4 in the complement cascade. (A). The classical pathway 
is activated when C1q binds to distinct structures on pathogens or damaged cells directly or 
through different molecules (for example IgG, IgM and CRP). Subsequently the proteases of the 
C1 complex, C1r and C1s are activated, C1r cleaving first C1s, which cleave C4 into C4a, 
anaphylatoxin and C4b. The lectin pathway is activated through mannose-binding lectin and 
ficolins recognizing carbohydrate patterns. The MASP-proteases are subsequently activated. 
MASP-1 cleaves only C2, whereas MASP-2 cleaves both C4 and C2. MASP-1 is though to 
amplify the lectin pathway, but a C4- and C2-independent activation pathways may also be 
functioning (continuous line). (B). The cleavage of C4 uncovers an internal thioester bond in 
C4b, which can covalently bind to adjacent carbohydrate or protein stuctures by forming ester 
or amide bonds, respectively. If a suitable target is not found, the C4b is inactivated into iC4b. 
The surface-bound C4b binds to C2, which is cleaved into C2a and C2b by MASP 1 or 2 or 
C1s. The resulting C4bC2b is a C3 convertase that cleaves C3 164, 174-176 177. 
 
C4A (acidic C4) and C4B (basic C4) genes are distinguished from each other by five 
nucleotides. The protein isoforms have differences in their biological actions, 
electrophoretic mobility, activated tertiary structures and disease associations (Table 8). 
Contradictory findings have been reported on the binding of complement receptors 178. 
However, the exact binding profiles and the extent to which different isotypes or 
allotypes affect the function of classical and lectin pathways is not known. Alternative 
splicing and glycosylation might also affect the biological responses 164. 
 
 
Table 8 
   
Characteristics of complement C4A and C4B   
 C4A (acidic) C4B (basic) Reference 
Synonyms C4F (fast) C4S (slow)  
Number of alleles At least 14 At least 17 179
 
Most common allotype C4A 3 C4B 1 180
 
Structure    
Number of exons 41 41 181
 
AA in positions 1120-
1125 
PCPVLD LSPVIH 182
 
Length Usually long (21kb) Long (21 kb) or short 
(14.6 kb) 
180
 
Rh/Ch antigen Usually Rodgers  Usually Chido 180
 
Function    
Specificity Amino groups Hydroxyl groups 183
 
Hemolytic activity low high 184
 
Deficiency    
Association with HLA TNF!-308A, CYP21A2 
656, 861 and 2761, 
LTA+252G, 
TNFa-238A, HLA-
DRB1*01, LTA +633C, 
CYP21A2 1106, 1113, 
1559 and 2209 
23, 28, 30 
Association with haplotypes limited various 185, 186 
Abbreviations; TNF!, tumor-necrosis factor alpha; CYP, cytochrome P450; LTA, lymphotoxin alpha. 
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The genetic variation of C4 is the greatest in the whole complement cascade. Genes 
encoding C4 are embedded in the RCCX module, a gene cluster consisting of functional 
and non-functional genes (Figure 11). The RCCX module consists of serine-threonine 
kinase, C4 (A or B), steroid 21-hydrolase (CYP21) and tenascin-X. In each chromosome, 
one to four RCCX modules may be seen (mono-, bi-, tri- and quadrimodular 
chromosomes). At least 20 different possible RCCX haplotypes and 17 diploid 
combinations can be present. In almost half of the cases, two C4 genes are present in both 
chromosomes 180. The CNV of total C4 is mainly between 2 and 6, but eight copies have 
been reported 164. The CNV of C4A varies between zero and five, and between zero and 
four in C4B 186-192. C4 genes may harbour also silencing mutations 193. 
 
 
 
Figure 11. The RCCX-structure. The duplications of CYP21 (CYP21A), TNX (TNXA) and RP 
(RP2) are pseudogenes (in white). In trimodular and quadrimodular structures, the duplicated 
CYP21 can be either CYP21A (aka. CYP21A1P) or CYP21B (aka. CYP21A2). Due to 
recombination events, CYP21A can be found also in monomodular structures and TNXA can be 
transformed into TNXB-like functional gene. A C4 gene in RCCX may be short or long and encode 
C4A or C4B. The duplicated C4 genes are usually functional, but may also have silencing mutations. 
Adapted from Szilagyi et al. 185 and Saxena et al. 192. 
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2.2.4.1 C4 deficiency 
 
C4 deficiency is historically defined as a low amount of C4A or C4B proteins. This may 
result from genetic factors (gene deletion, gene conversion or silencing mutations) or 
increased consumption (Figure 12). C4 deficiencies are classified into complete (absence 
of all functional C4 genes) and partial (lack of C4A or C4B gene[s]). Partial deficiencies 
are divided into homozygous (no C4A or C4B) or heterozygous deficiencies (one copy of 
C4A or C4B missing and one left). Due to the low frequency of complete and partial 
homozygous deficiencies, C4 deficiency is usually modelled as the presence of any C4A 
or C4B deficiency, thus overestimating the frequency of heterozygous partial C4 
deficiency. C4 deficiency due to low CNV for C4A is 11–22%, whereas for C4B it is 21–
41% in the general population 186, 189-191. In addition to the low amount of protein, some 
hemolytically inactive C4 alleles have been described 194, 195. These, together with some 
drugs, such as hydralazine and isoniazid can inhibit the function of C4 and cause a 
deficiency of functional C4 proteins 196.  
 
 
Figure 12. C4 deficiency.  
 
 
The relationship between the total numbers of C4 genes, the number of C4A and C4B 
genes and C4 deficiency is complex (Table 9). Low CNV (less than 2 copies of C4A or 
C4B) causes part, but not all phenotypic C4 deficiencies. CNV records deletions and 
conversions, but not the silencing mutations (Figure 12). The most common mutation 
!"#$%&'()*+
,#-*)#$*'+
./0+
1#2#3%$4+ .%$5#64)%$4+
78&93%$4+
.:)$4+ ;&"#64+
1#2#3%$+<#=%$+>?@+ABC+
D$4#63%$+<#=%$+AE@+?FC+
:69$4)3%$+<#=%$+>?@+)$&6%$+AGC+
.%$48H(3%$+
 30 
leading to C4A silencing is a two-nucleotide CT insertion in exon 29 (CTins), codon 1213 
and is virtually absent in C4B 197.  
In the literature, 28 individuals with complete C4 deficiency have been identified. All of 
them have developed systemic lupus erythematosus (SLE, n=17), a lupus-like disorder 
(n=5) or kidney disease (n=6). Other diseases are rrepeated and invasive infections 
(meningitis, osteomyelitis, otitis media, respiratory tract infection), recorded in seven 
patients. Five of these patients have died between the ages of 2 and 25. One individual 
was initially recorded healthy, but later developed haematuria and invasive infection 198. 
Even in the presence of complete C4 deficiency, there is at least one monomodular 
RCCX-structure, where the C4 gene is mutated into an inactive form 164. 
 
Table 9   
Relationship between C4 CNV, number of C4 genes and C4 
deficiency 
Number of 
C4 genes 
Possible C4A/C4B copy 
number combinations 
Possible C4 deficiency 
(A, B or both)b 
2 0/2 A 
 1/1 A, B 
 2/0 (A), B 
   
3 0/3 A 
 1/2 A 
 2/1 (A), B 
 3/0 B 
   
4 0/4 A 
 4/0 B 
 2/2 . 
 3/1 (A), B 
 4/0 B 
   
5 1/4 A 
 2/3 (A) 
 3/2 . 
  4/1 B 
a Assuming the presence of mono- to quadrimodular genotypes 
b (A) in case of CTins silencing C4A. 
 
 
Various infectious and autoimmune diseases have been associated with (partial) C4 
deficiency (Table 10). It is not known, whether the C4 deficiency itself or the linkage 
with the surrounding MHC are linked with SLE. Recent data suggests that C4A 
deficiency is not independently associated with SLE, but for C4B, the role of surrounding 
MHC is less important 199. On the other hand, however, partial deficiency of C4 can be 
very common in the general population that never develop SLE (see above).  
C4 deficiency has not been associated with renal transplant outcome 188. Recently, disease 
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associations have been extended beyond inflammatory and infectious diseases. The 
disease associations have also challenged the traditional dogma that links C4A deficiency 
with immune complex diseases and C4B deficiency with increased susceptibility to 
infections 166.  
The effect of the total number of functional C4 genes has only seldom been determined 
(Table 10). CTins has been rarely assessed in case-control settings in screening both cases 
and controls. One study with children surviving from meningococcal meningitis showed a 
two times higher, but statistically insignificant difference in CTins 190. CTins has not been 
shown to be associated with SLE 199.
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2.2.4.2 C4 deficiency in CAD 
Interest in the role of C4 in ACS was aroused by the observation that the frequency of 
C4B deficiency was lower in increasing age 214. This led to the hypothesis that diseases 
with high mortality, such as MI, could account for the observed decrease in the frequency 
of C4B deficiency. Since then, the finding of the decreased frequency of C4B deficiency 
in the elderly has been replicated 215.  
The role of complement C4 deficiency in CAD is controversial (Table 11). C4B 
deficiency has been associated with STEMI 21 and with CAD in patients undergoing 
GABG 28, but was not increased in patients with history of MI 28. C4A deficiency and 
tumor necrosis factor alpha -308A SNP have been associated with CAD and history of 
MI 28.  In the study with a positive association with C4B deficiency and STEMI was seen 
only when patients were compared against with controls of over 60 years, in whom the 
frequency of C4 was previously shown to be decreased when comparing with younger 
population 21, 216. In addition, in this study, the serum C4 allotyping was performed 
directly after the diagnosis of STEMI, why the increased complement consumption might 
bias the results (See section 2.2.5). On the other hand, no association was found with C4 
deficiency and premature MI or MI during follow-up 217, 218. The possibly increased 
mortality after MI might explain the discrepant findings, but these data are based on less 
than 30 patients 21, 30.  
Subgroup analyses have linked C4B deficiency with CAD/MI in smokers, but the raw 
data was not given in all studies and the patients were selected by two characteristics and 
may not thus be generalized (Table 11) 29, 21, 30. One study reported association of C4 
deficiency and CAD among current smokers over 50 years in Icelandic population. 
However, the age dichotomization was performed on the basis of controls, in which a 
sharp decrease in the frequency of C4B deficiency in smokers was seen after 50 years of 
age. A confirmatory analysis of a different ethnic group was performed, but the number 
of cases versus controls was very small. In addition, the interaction term was not tested 29. 
In another study, the role of C4B deficiency in smoking was tested also on one-year 
mortality after MI. An association was seen in the whole population and in ever smokers 
30. The interaction term was significant, but the number of current smokers was small and 
thus the comparison was made between ever vs. never smokers. 
C4 deficiency might be linked with CAD by functioning as a marker for the real CAD-
predisposing genetic variation. C4A deficiency associates with certain SNP markers in 
introns in the MHC III cluster (r2 from 0.44 to 0.6) and with DRB1*03 (r2 from 0.03 to 
0.049). For C4B, the linkage is consistently lower, but DRB1*01 and SNP in the central 
region have been described (Table 7). Of the described markers, DRB1*01 has been 
associated with CAD (Table 6), whereas the role of others C4-deficiency linked markers 
is not known.  
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Table 11     
Studies addressing C4 deficiency and CAD     
  N (cases/ 
controls) 
Isotype 
deficiency 
Phenotype OR (95%CI) Reference 
Association     
 181/737 C4B STEMI N.A. 21
 
 28/153 C4B Mortality from STEMI N.A. 21
 
 24/118 C4Ba Mortality from MI 4.13 (1.65–10.37) 30
 
 318/248 C4B >70% stenosis in patients with 
CABG 
1.5 (1.0–2.1) 28
 
 318/248 C4A and 
TNF!-308A 
>70% stenosis in patients with 
GABG 
2.2 (1.3–3.8) 28
 
  158/162 C4A anamnestic MI in patients with 
CABG 
1.9 (1.2–3.1) 28
 
No association    
 100/164 C4A or C4B STEMI in young patients Ns 215
 
 118/134 C4A or C4B STEMI during follow-up Ns 215
 
 100/90 C4A or C4B STEMI in young patiente Ns 217
 
Subgroup analyses    
 24/50 C4Ba First MI in smokers in >50 
years 
22.66 (2.45–206.59) 29
 
 23/50 C4Ba History of MI in smokers >50 
years 
Ns 29
 
 19/50 C4Ba Angina pectoris, >50 years and 
smoker 
30.07 (1.93–469.15) 29
 
 130/17 C4Ba CAD and >50 years and 
smoking 
8.90 (1.12–70.98) 29
 
 N.A. C4B Men over 60 years 7.57 (3.31–17.2) 21
 
 N.A. C4Ba Survival after acute MI in ever 
smokers 
3.50 (1.38–8.87) 30
 
Abbreviations; N.A, not available; Ns, not significant; GABG, coronary artery bypass by 
grafting; TNF!, tumor-necrosis factor alpha; OR, odd’s ratio; 95%CI, 95% confidence 
interval). 
          a Genotypic analysis. 
 
 
 
2.2.4.3 Complement in CAD 
 
The role of the complement system in CAD is complex. The complement system may be 
connected with CAD locally or systemically and by the induction of too strong or 
alternatively by insufficient activation as well 58. It is not known, what is sufficient, but 
not too extensive complement activation for optimal cardiovascular health. In human 
studies, genetic variation causing low phenotypic levels in classical and in lectin 
pathways, namely C4, C2 and mannose-binding lectin deficiencies, have been associated 
with CAD/MI 22, 185, 219. Animal models have shown that knocking out C1q 220 and 
mannose-binding lectin increase plaque size, suggesting that early classical and lectin 
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pathway activation is protective of atherosclerosis. Animal models also indicate that the 
activation of alternative pathway and the presence of membrane-attack complex may be 
atherogenic 58. These data are not conclusive, and on the other hand, in the deficiency of 
C1 inhibitor, the cause of hereditary angioedema, the risk of atherosclerosis might also be 
increased 221. To complicate things further, serum mannose-binding lectin levels have 
been proposed to have an U-shaped association with CAD 222. For C4, very high serum 
levels have been associated with MI 223. Also low C4 levels, transcribed in the serum 
C3/C4 ratio have also been linked with cardiovascular disease 224. 
In addition to the pathogenesis of CAD 225, the complement system may have an 
important role in the ischemia-reperfusion injury and tissue repair after MI 226. 
Pexelizumab, an antibody preventing the cleavage of C5 has been studied in MI and with 
coronary artery bypass by grafting in preventing the ischemia-reperfusion damage. The 
results in coronary artery bypass surgery have been positive 227, but for STEMI, the 
administration of pexelizumab after two hours after the onset of cardiac pain may be too 
late to prevent terminal complement activation 228. The role of complement in ACS is 
difficult to assess as the decreased serum levels might be caused by increased 
consumption in the acute setting, thus reflecting a large infarction. On the other hand, 
complement components are induced in the acute setting and increased serum levels 
might also reflect large acute tissue damage.  
The complement participates in tissue homeostasis and lipoprotein metabolism, has 
interconnection with coagulation and bradykinin systems, modulates the innate and 
adaptive immune reactions and participates in host defense against microbes and 
abnormal cells in more distant locations 229, 230. Given the complexity of the pathogenesis 
of CAD, it seems highly likely that also the systemic reactions of complement are 
important 52, 53. 
 
2.2.5 METHODS FOR MHC GENE ANALYSES 
 
The analysis of MHC I and II alleles was originally based on serology (complement-
dependent cytotoxicity assay). From the 1980’s onwards, restriction fragment length 
polymorphism, reference standard conformational analysis and later polymerase chain 
reaction (PCR) methods have been used in the HLA-allele analyses. The PCR methods 
include sequence-specific oligonucleotide probe, sequence-specific primer amplification, 
single-strand conformation polymorphism, sequence-based typing and microarray 
applications (Table 12). These methods are usually applied for the analysis of an 
individual’s HLA alleles. Sequence-specific primer amplifications are also used for the 
detection of a single HLA-allele of interest, such as B*27 for ankylosing spondylitis and 
B*15:02 for abacavir hypersensitivity 231. Lately, the SNP panels are becoming more 
intensely mapped with MHC, rending the imputation of HLA-alleles into large sample 
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sizes 26, 27. According to our experience, the imputation may need a reference population 
of the same genetic background in order to accurately determine the HLA-alleles. 
Various methods for C4 genetic analyses are available (Table 13). C4 CNV was first 
indirectly assessed by immunophenotyping the plasma C4 proteins 232. Restriction 
enzymes with southern blotting was amongst the first genetic methods for assessing 
RCCX module composition and C4 CNV 233. Subsequently various PCR-based methods 
were developed 234. Newer methods include paralog ratio test 186 and multiple ligation 
probe analysis 190. SNP variation has not been linked with C4 CNV status and thus the C4 
genetic status is not recorded in GWAS 199.  
There are also methods for detecting the deletion of C4A 235, the presence of C4A/C4B 
genes 236, the C4A to C4B gene dosage and C4 module number 233. CTins has been 
detected by sequencing or direct PCR 237, with multiple ligation probe analysis 190 and 
paralog ratio test, but it has not been reported with quantitative polymerase chain reaction 
(qPCR). SNPs have not been associated with CTins presence 197. 
 
Table 12     
Comparison of assays for genetic HLA-allele analyses 
Method Principle Through 
output 
Resolution Cost 
Imputation SNP haplotypes are inferred as HLA-
alleles based on reference individuals 
with in-depth sequence and HLA-allele 
data. 
High High High 
RFLP Differentially digested DNA fragments 
are separated by electrophoresis. 
Low Low Not commonly 
used 
RSCA DNA is hybridized to probes and the 
mismatches are differentiated by 
electrophoretic mobility. 
Low Low Not commonly 
used 
PCR     
SSO PCR amplicon is hybridized with a 
specific oligonucleotide probes. 
High Medium Low 
SSP Several PCR reactions specific for a 
certain alleles. 
Low Low, 
medium or 
high 
High 
SSCP Amplified DNA is run on a gel. 
Different alleles differ by secondary 
structures and thus by migration 
patterns. 
   
SBT Amplified DNA is sequenced by 
primers. 
Low High High 
Microarrays Amplified DNA is bound to specific 
probes and detected by lazer. 
Low High High 
Next-generation 
sequencing 
DNA or PCR fragments are separated, 
immobilized by adaptors and analyzed 
individually. 
High High High 
Abbreviations; RFLP, restriction fragment length polymorphism; RSCA, reference standard conformational 
analysis; PCR, polymerase chain reaction; SSO, sequence-specific oligonucleotide probe; SSP, sequence-specific 
primer amplification; SSCP, single-strand conformation polymorphism; SBT, sequence-based typing.  Data adapted 
from Smith 231, Davies at al.,26 and Takeuchi et al.27. 
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2.3 INFLAMMATION, AUTOIMMUNITY AND INFECTION IN ACS 
 
2.3.1 INFLAMMATION 
 
Atherosclerosis is considered to be an inflammatory disease 50. This is emphasized by the 
abundance of inflammatory cells, cytokines and inflammatory markers within the plaque. 
Inflammatory features have also been associated with the plaques that are ruptured 65. 
Even though inflammatory features within the eroded plaques are not as prominent, 
inflammation has been suggested to be involved with plaque erosions as well 238 (see 
Sections 2.1.2.1 and 2.1.2.2). In addition, inflammation may also alter the lipoprotein 
metabolism and the thrombogeneity of blood, favouring ACS 52, 68. However, ACS is 
caused by other factors than plaque rupture and erosion (Table 1) and inflammation is not 
the only factor in the pathogenesis of ACS (Figure 5) 68. 
CRP is an unspecific marker of the systemic inflammatory level 239. CRP is present in 
atherosclerotic plaques. High serum levels of low-grade inflammation (serum hsCRP) 
have also been associated with MI 240, with plaque characteristics that are prone to rupture 
65 and predictive of future MI 241. Elevated serum hsCRP levels have been shown to have 
similar correlation over time with other measurable cardiovascular risk parameters 241. 
CRP itself may cause various pro-inflammatory biological responses 242 but it is currently 
believed that elevation in hsCRP reflects the inflammatory state and is not causative by 
itself 243-245. In addition, hsCRP is neither sensitive nor specific in predicting MI 240. 
The causality of inflammation on the pathogenesis of ACS has not been shown, although 
current data supports this assumption. Inflammatory reactions may also be involved in 
tissue repair after atherogenic injury and be advantageous in certain conditions 246. In the 
future, imaging techniques and novel therapeutic strategies will help to identify the role 
of inflammatory processes in CAD and ACS. Treatment options against proinflammatory 
factors include the increase of high-density lipoprotein (HDL) by HDL-mimetics, 
inhibition of lipoprotein-associated phospholipase A2 by darapladip, inhibition of matrix 
metalloproteinases by tetracyclines, inhibition of thrombin by melagatran, inhibition of 
cytokines (IL-18, IL-12, IL-23), blocking chemokine or cytokine receptors (CCR2, IL-1-
receptor, MIF, CCR5), directly targeting specific interactions in immune cells (CCL5-
CXCL4), inducing tolerance by vaccination, antigen-loaded DCs or mucosal 
immunization and selective B-cell depletion by antibodies 53, 54, 247, 248. 
 
2.3.2 INFECTION  
  
Infection was first associated with atherosclerosis in animal models 249, 250. In human 
studies, conditions such as Chlamydophila pneumoniae (Cpn) infection, acute respiratory 
and urinary infection and chronic periodontal infection have been associated with 
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increased risk for MI 251-253. In addition, various infective pathogens have been associated 
with CAD/IHD/MI in different levels of evidence (Table 14). Infection could be involved 
in coronary atherosclerosis at increasing the systemic inflammatory rate, inducing 
autoimmunity (through for example molecular mimicry), by direct infection of the cells in 
atheroma 254, by activating platelets 255, by production of immunomodulatory agents 256, 
by activation of DC 257 or by direct damage to the cells by toxins 258. On the other hand, 
cross-reactive antibody production might also be protective 259.  
No infectious agent has been shown to cause atherosclerosis. There is still debate 
concerning the methodology of pathogen detection and the role of one versus several 
pathogens, named the pathogen burden hypothesis. Evidence exists that influenza 
vaccination decreases mortality, but this does not suggest causality. More studies are 
needed to replicate the role of influenza virus in ACS 254, 260. 
 
Table 14        
Examples of infections in CAD 
Infectious agent 
Sero-
epidemiology  
Immuno-
histochemistrya 
Electron 
microscopya 
Nucleic 
acidsa 
In situ 
hybridization
a 
Viable 
micro-
organismsa 
Chlamydophila 
pneumoniae 
+  + + + + + 
Mycoplasma pneumoniae +   +  +  
Porphyromonas gingivalis -  +  +  - 
Aggregatibacter 
actinomycetemcomitans 
-    +   
Cytomegalovirus +  +     
Herpes simplex viruses +  + + + +  
Hepatitis virus B +       
Hepatitis virus C +       
Helicobacter pylori     +   
Fungi         +     
Adapted from Lockhart et al. 254 and Rosenfeld and Campbell 13. 
a Detected within atherosclerotic plaque. 
 
2.3.2.1 Chlamydophila pneumoniae (Cpn) 
 
Of the studied microbes, Cpn has the strongest evidence of associating with coronary 
atherosclerosis (Table 14). The mechanisms through which Cpn infection may be 
pathogenic include the infection of endothelial cells, macrophages and SMCs. When 
infected, these cells undergo changes in surface composition and cellular function. In 
addition, the release of chlamydial heat shock protein 60 (HSP60) may be 
proinflammatory 246.  
However, all large-scale antibiotic treatments for targeting Cpn have failed to show 
benefit, regardless of the serological status of Cpn (Table 15). As these antimicrobial 
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agents have not shown to efficiently eradicate the chronic forms of Cpn and they do not 
inhibit the possibility of reinfection, it is not possible to assess the effect of Cpn in 
ACS/CAD based on these data. Therefore new strategies for treating chronic Cpn 
infection have been suggested. These include targeting the important molecules in 
replication, survival and infective properties of Cpn as well as host pathways that are 
though to mediate the adverse inflammatory responses caused by Cpn 261.  
 
Table 15        
Randomized clinical trials for secondary prevention of CAD/ACS 
Reference n= Treatment Daily dosage Duration Follow-
up (yrs) 
Outcome Result 
       
Stable CAD/MI survivor       
262
 
60 AZ 500 mg 3d 1.5 Death, ACS Beneficiala 
263
 
4373 CF 500 mg 14d 3 Death, ACS Ns 
264
 
302 AZ 500 mgb 3mo 2 Death, ACS, stroke, 
revasc 
Nsa 
265
 
7747 AZ 600 mgc 3mo 2.5 Death, ACS, revasc Ns2 
266
 
4012 AZ 600 mg 
weekly 
12mo 3.9 Death, ACS, revasc Ns 
ACS        
267
 
325 AZ 500 mg 7d 1 Acs Beneficial 
268
 
202 RX 150 mg x2 1mo 0.5 Death, ACS Ns 
269
 
872 RX 300 mg 1.5mo 1 Death, ACS, stroke Ns 
270
 
4162 GF 400 mgd 3mo 2 Death, ACS, stroke, 
revasc 
Ns 
271
 
148 CF 500 mg 3mo 3 Death, ACS, stroke Beneficial 
272
 
84 RX 150 mg x 2 1mo    
PCI      Death, ACS, revasc  
273
 
1010 RX 300 mg 1mo 1 Restenosis, MI Ns 
Meta-analysis        
274
 
19217 macrolides   Death or ACS Ns 
275
 
25271 all antibiotics  Death Increased 
risk 
276
 
25009 all antibiotics 
  
  Death or ACS or 
compositee  
Ns 
Abbreviations; AZ, azithromycin; CF, clarithromycin; RX, roxithromycin; GF, gemfibrozile; revasc, revascularization; 
PCI, percutaneous coronary intervention; d, days; mo, months; ns, no treatment effect. 
  a High Cpn titers.       
b for three days, subsequently one per month. 
c for 3 days, then 600  mg weekly. 
d daily for 2 weeks, then 10-day course each month. 
e Subgroups; stable/unstable, Cpn infection and type of antibiotic. 
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2.3.2.2 Macrolides in ACS 
 
Macrolides are a collection of antimicrobial molecules sharing a macrocyclic lactone ring 
of variable size. Macrolides were discovered in 1952, isolated from Streptomyces 
erythraea. The most common macrolides are erythromycin, clarithromycin, 
rozithromycin (14-atom lactone ring) and azithromycin (15-atom lactone ring). 
Macrolides affect a moderately broad range of aerobic and anaerobic, mostly gram-
positive bacteria. They are used for common respiratory tract and skin infections 277. 
The 14- and 15-membered ring macrolides have pleiotropic effects, discovered in the 
1980’s when patients with diffuse panbronchiolitis, were reported to experience 
amelioration during erythromycin treatment 278. The beneficial effect is thought to result 
from antimicrobial and anti-inflammatory actions, alone or combined (Table 16). 
Macrolides are used as maintenance treatment for chronic inflammatory pulmonary 
diseases such as cystic fibrosis, chronic sinusitis and bronchiectasis, but evidence for 
macrolide use on these conditions is not solid 279. The treatment of CAD by macrolides 
was not beneficial and some studies even reported adverse effects (Table 15). 
 
 
Table 16  
The effects of macrolides 
 Effect Mechanism 
Antimicrobial  
Gram-positive cocci, 
limited gram-negative 
activity, possibly 
intracellular pathogens 
Inhibition of protein synthesis 
Direct lysis 
Attenuation of biofilm formation 
Attenuation of bacterial communication (quorum sensing) 
Decreased adherence 
Impaired mobility 
Decreased production of bacterial toxins 
Increased intracellular concentration 
Cell surface alteration 
Anti-inflammatory  
cytokines Decreased synthesis/secretion of proinflammatory cytokines 
 Increased release of anti-inflammatory cytokines 
macrophages Promotion of phagocytosis of apoptotic cells 
 Increased differentiation 
 Enhanced function 
Neutrophils Reduction to chemokines 
 Stimulation of exocytosis 
 Increased apoptosis 
Endothelium Decreased adherence molecule expression 
T cells Increased apoptosis of activated cells 
 Increased Th1/Th2 ratio 
Dendritic cells Increase of CD80 costimulatory molecule 
 Inhibition of IL-6 and IL-2 production 
B-cells Contradictory findings 
Most of the data is derived from in vitro or animal models and is by no means conclusive 277, 280. 
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For clarithromycin, the reported adverse effects are gastrointestinal adverse reactions 
(9%), rash (0.5–6%), hepatotoxicity, cardiotoxicity and ototoxicity. Cardiotoxicity is 
related to QT-interval elongation and cytochrome P450 inhibition of other 
proarrythmogenic drugs 279. In addition, clarithromycin may subject to rhabdomyolysis in 
interaction with statins 281. Sudden cardiac death has been associated with erythromycin, 
clarithromycin and azithromycin use 282-284. Currently antimicrobial agents such as 
tetracyclines are under investigation for their anti-inflammatory mechanisms for the 
treatment of CAD 285. 
 
2.3.3 AUTOIMMUNITY  
 
Autoimmune reactions mainly directed against native and oxidated low-density 
lipoprotein lipase (LDL) and heat shock proteins are involved in the pathogenesis of 
CAD, possibly in an Ig-class specific way. Different Ig classes differ in their ability for 
example in activating complement 53 286. The risk of ACS is also increased in 
autoimmune rheumatic conditions, due to inflammatory factors, traditional risk factors 
and treatment 287.  
 
2.3.3.1 Heat shock protein 60 (HSP60)  
 
HSP60 (also referred as HSPD) is a mitochondrial protein. The gene for HSP60 is located 
in chromosome 2. HSP60 is present in various cell types and is also found in cytosol, cell 
surface and in soluble form HSP60 (sHSP60). Bacteria have also HSP60, which shares 
great sequence homology with human HSP60 288, 289. In atherosclerotic plaques, cell 
surface HSP60 is seen on endothelial cells, macrophages, foam cells and sometimes on 
SMCs, but only rarely on normal arterial intima 290. Cell surface HSP60 is a target for 
HSP60 antibodies 291, 292. HSP60 on cell surfaces may be involved in cellular signaling, 
membrane transport and immune signaling 288. 
sHSP60 may originate from secretion or release from stressed or damaged cells. sHSP60 
is present in healthy individuals, but high levels of sHSP60 have been associated with 
CAD 293 and with the extent and severity of CAD 294. Risk factors such as infection, 
smoking, oxLDL, blood pressure and drugs lead to increase in HSP60 expression levels 
295. The levels of sHSP60 may vary among different ethnic groups 296. An individual’s 
sHSP60 level has been shown to remain stable over 5 years (r=0.40) 297. sHSP60 is 
independent 293, 298 or weakly correlated with HSP60 antibody levels (r=0.26) 297, 
suggesting that antibodies are not involved in the elimination of sHSP60.  
Increased plasma HSP60 is associated with MI 293. Extracellular HSP60, or fragments of 
it, activate innate and adaptive immune cells. The effect might be pro- or anti-
inflammatory, depending on the concentration and type of the receptor engaged. HSP60 
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may be a self-antigen, a foreign antigen, a carrier of functional molecules and a ligand for 
Toll-like receptor signaling 289. 
The role of HSP60 in immunity is complex (Figure 13). HSP60 itself is an immune-
modulating molecule, and antibodies to HSP60 are present in all individuals. Antibodies 
to bacterial HSP are though to result in resolution of infection, but elevated levels of 
HSP60 antibodies are linked with various autoimmune-like disorders such as type 1 
diabetes mellitus, rheumatoid arthritis, multiple sclerosis, Bechet’s disease, SLE, 
inflammatory bowel disease and vasculitis 289, 299.  
 
 
 
Figure 13. Different aspects of HSP60 immunity in atherosclerosis. Various stressors and 
infection increase the amount of surface-bound HSP and free endogenous HSP, which may have 
inflammatory properties. Exogenous HSP results from infection. Immune responses against 
bacterial HSP60 are usually involved in infection and vaccination. These antibodies cross-react 
with human HSP60. Autoimmunity to HSP60 is present in all individuals and it may be involved 
in inflammatory signaling. Modified from Alard et al. 300 and Quintana et al. 289. 
 
High levels of IgG antibodies against human HSP60 have been associated with 
CAD/MI293, 301-303. Human HSP60 IgA, but not IgG HSP60, antibodies have been shown 
to predict future MI 304, 305. Animal models have shown that HSP60 antibodies are 
causative in atherosclerosis 306. The origin or the biological response to elevated HSP60 
autoantibodies is not known, but all individuals have antibodies against HSP60. They 
might result from infection, elevated sHSP60 or be genetically determined as a part of 
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natural antibody repertoire 14, 293. HSP60-reacting antibodies could be proatherogenic by 
causing endothelial cell apoptosis 307, thrombus formation 308 or complement- and cell-
mediated lysis of (endothelial) cells 292. HSP60 antibodies may also modulate or 
potentiate immune reactions 309.  
T-cell immunity to HSP60 might also be important. T-cell reactivity in atherosclerotic 
plaques, but not in peripheral blood has been reported 291. In animal models, tolerization 
to mycobacterial HSP60 has been shown to reduce plaque size 310, 311.  
Antibodies to bacterial HSP60 are also linked with CAD/ACS 303. However, these 
antibodies may have different epitope specificity and different biological properties than 
the antibodies against human HSP60 303. The HSP60 autoantibody levels remain constant 
over time, suggesting constant production or genetic control 312. The anti-human HSP60 
autoantibodies might be bacterial HSP60 antibodies that cross-react with human HSP60, 
or a part of natural antibody repertoire. Alternatively they might arise from recognition of 
modified human HSP60 or in a T-cell independent manner by stimulation of B-cells 289.  
 
3.3.3.2 Other HSPs 
 
HSPs 70, 27 and 90 have also been found in atherosclerotic plaques. The role of sHSP70 
and HSP70 antibodies in CAD is controversial 313, 314, but HSP70 immunology might be 
involved in ischemia-reperfusion injury 314, 315. sHSP27 has not been shown to associate 
with future cardiovascular events 316. sHSP90 and HSP90 antibodies are associated with 
carotid atherosclerosis 317, but their role in CAD is not known. 
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3. AIMS OF THE STUDY 
 
The aims of this Thesis were 
 
I. To develop a novel qPCR method for genetic C4 analyses (I). 
 
II. To confirm the role of MHC genes and haplotypes in two clinically different ACS 
populations (II, III, IV). 
 
III. To identify the possible effect of ACS-related MHC genes on inflammatory and 
infectious reactions by studying 
a. the response to secondary prevention trial of macrolide treatment (II), 
b. hsCRP as a marker for the general inflammatory level (III), 
c. the level of autoantibodies to HSP60  (IV). 
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4. MATERIALS AND METHODS 
4.1 STUDY MATERIALS 
 
The qPCR method was applied on three different materials (I; Table 17). The patient 
samples consisted of all of our HLA-Laboratory’s samples between November 2004 and 
December 2009 that had both C4 qPCR and immunophenotyping results (n=1648). Sixty 
per cent of these samples were sent from the Division of Infectious Diseases in Helsinki 
University Central Hospital, representing mainly infection prone patients (personal 
communication, A. Järvinen, Chief Physician). Genomic DNA from cell lines of 
consanguineous subjects (n=48) was purchased from the International Histocompatibility 
Working Group Cell Bank (Seattle, WA). Two samples (IHW09038 and 09102) were not 
available. The C4 CNV status has been previously published 234. HapMap samples (n=89) 
were obtained from Coriell Cell Repositories. The C4 genetic status was assessed by 
southern blotting and paralog ratio test 186. Method validation was performed on seven 
samples from our Laboratory and on six cell bank samples. The validation was performed 
by replicating the analysis from two different dilutions and in various independent runs. 
The NSTE-ACS population (II, IV) was initially collected for a prospective randomized, 
placebo controlled, double blind secondary prevention trial of ACS between September 
1998 and December 2000. The samples were collected from nine hospitals in different 
parts of Finland (Southern n=91, Central n=20 and Western n=37) 271. The population 
consisted of cases suffering form UAP (n=43) or NSTEMI (n=105) according to the 
definition of MI at the time (Table 17).  A serum sample for C4 analysis was available 
from 144 patients (97.3%). The secondary prevention was daily oral administration of 
clarithromycin (500 mg) or placebo for three months (85 days). During the average 
follow-up of 555 days (range 138 to 924 days), recurrent cardiovascular events (death, 
stroke, myocardial infarction or UAP) were recorded. Controls were age- and sex 
matched blood donors (n=74) that can be regarded as healthy since the presence of CAD, 
stroke, hypertension, hypercholesterolemia, diabetes mellitus were considered as 
contraindications for blood donation (IV) 23.  
The STEMI patients (III; n=203) were initially recruited for an open, nonrandomized 
study comparing thrombolysis and primary percutaneous coronary intervention between 
April 2004 and April 2005 318 (Table 17). Patients receiving thrombolysis underwent 
coronary angiography within 180 minutes after lytic therapy. There was no exclusion by 
age- or comorbidity. For the genetic analyses, samples were available from 162 cases 
(80%). Death before sample collection (n=17), no treatable lesion (n=6), lack of sample 
(n=17) and coronary artery bypass by grafting (n=1) were the reasons for not obtaining a 
sample. Controls were age- and sex matched cases without angiographic evidence of 
CAD (stenosis <50%), no evidence of cardiac biomarker leak, no anamnestic MI and no 
CAD-related intervention (n=319). The controls underwent coronary angiography and 
were selected from the COROGENE-cohort 319.  A reference population (n=150) that 
consisted of healthy subjects undergoing a health survey before accepting a new 
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occupational post was included 191. One reference population sample was excluded due to 
degraded DNA. 
Age matching was done with ! 5 years difference in both studies. Baseline characteristics 
were drawn from hospital records and from patient questionnaires. Background 
information was not available from the NSTE-ACS controls or the reference population.  
 
Table 17    
Patient populations 
  
    
Study 
Number of 
subjects 
Samples 
available Inclusion criteria Exclusion criteria 
Patients   
I 1648 1648 Genetic and phenotypic C4 
analysis. 
None. 
II, IV 148 144/143a Accelerating or prolonged anginal 
pain with minimal effort/exertion 
<48hours before randomization and 
transient ST-elevation, new ST-
segment depression or T-wave 
inversion (transient or persistent) or 
cardiac biomarker leak. 
Lack of consent, previous STEMI 
within 48 hours, ongoing antibiotic 
therapy, STEMI or thrombolysis 
within 48 hours, PCI or GABG 
performed in past six/three months 
or these planned, age<18 or >90 
years. 
III 203 166 Prolonged anginal pain 
accompanied with a novel ST-
elevation. The onset of pain !12 
hours. 
Lack of consent, LBBB, 
contraindication for anticoagulants, 
blood pressure >160/110 after 
initial treatment or violation of 
time constraints. 
Controls    
I 50 48 All available IHWG samples. None. 
I 89 81 Samples with concordant result in 
southern blotting and paralog-ratio 
test. 
None. 
III 319 319 Age- and sex matching, <50% 
stenosis in angiography. 
Lack of consent, anamnestic ACS, 
PCI or GABG, current cardiac 
enzyme elevation. 
III 150 149 Participation to a health survey 
before accepting a novel 
occupational post. 
Lack of consent. 
IV 74 74 Consecutive age- and sex matched 
blood donors. 
None in addition to 
contraindications for blood 
donation. 
Abbreviations; STEMI, ST-elevation myocardial infarction, PCI, percutaneous coronary intervention; GABG, 
coronary bypass by grafting; LBBB, left bundle-branch block; IHWG, International Histocompatibility Working 
Group. 
a In Study II/IV, respectively   
Definitions: 
ST-segment elevation or depression >0.1mV in at least two extremity leads or >0.2mV in precordial leads. 
Proloned anginal pain >20 minutes   
T-inversion >0.3mV in at least three extremity or precordial leads (excluding V1). 
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4.2 METHODS 
 
The studied parameters varied within different populations and are summarised in Table 
18. The details of each analysis are described below. 
 
Table 18   
Laboratory analyses   
Population HLA markers Serum parameters 
Infection-prone patients 
(I) 
C4 CNV _ 
NSTE–ACS (II, IV) HLA-A, HLA-B and HLA-
DRB1 alleles, C4 allotypes 
and four LTA SNPs 
hsCRP, anti-hHSP 60, cardiac 
biomarkers, pro-BNP, lipids, 
leukocyte count, antibodies to 
Cpn, C3 and C4 concentrations 
Controls (IV) HLA-A, HLA-B and HLA-
DRB1 alleles, C4 allotypes 
and four LTA SNPs 
Antibodies to Cpn 
STEMI (III) HLA-B*35, HLA-DRB1*01 
and C4 CNV 
hsCRP, cardiac biomarkers and 
lipids 
Controls (III) HLA-B*35, HLA-DRB1*01 
and C4 CNV 
hsCRP, cardiac biomarkers and 
lipids 
Population sample (III) HLA-A, HLA-B and HLA-
DRB1 alleles, C4 allotypes 
and C4 CNV 
hsCRP 
Abbreviations; CNV, copy number variation; LTA, lymphotoxin alpha; hsCRP, high sensitivity C-
reactive protein; hHSP, human heat shock protein; BNP brain natriuretic peptide; Cpn, Chlamydophila 
pneumoniae; C3, C4, complement components 3 and 4. 
Definitions: 
Cardiac biomarkers; troponin T, troponin I or creatine kinase MB-mass. 
Lipids; total cholesterol, low-density lipoprotein lipase, high-density lipoprotein lipase and    triglycerides. 
 
 
4.2.1 DNA ANALYSES 
 
4.2.1.1 Isolation 
 
Genomic DNA was isolated using the Manufacturers’ instructions. For cases, NucleoSpin 
® QuickPure (Macherey-Nagel, GmbH & Co. KG, Düren, Germany; I, III) or Genta 
Puregene Kit (Qiagen, Vienna Austria; II, IV) were used. For controls, Autopure LS® 
with Puregene (Qiagen; III), Gentra Puregene (Qiagen) or salting out (II, IV) 320 were 
used. For the reference population sample, Gentra Puregene Kit (Qiagen; III) was used. 
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4.2.1.2. Primers 
 
The primer sequences and detailed information on the qPCR protocols are given in Table 
19. 
 
 
Table 19     
Annealing temperature, master mix, amplicon size and analysis threshold for each qPCR 
qPCR run Specificity Primer sequence 5’–3’ 
SYBR® 
Green Mix 
Annealing 
temperatur
e (ºC) 
Analysis 
threshol
d 
HLA-B*35_1 B*35_f GTCCGAGGACGGAGCCCCG ABsolute
™ 
60 0.05 
 B*35_r GTAGCCGCGCAGGTTCCGC 
  
HLA-B*35_2 B*35_f CCGCTTCATCGCAGTGGGC ABsolute
™ 
60 0.05 
 B*35_r GTGTTGGTCTTGAAGATCT  
  
HLA-
DRB1*01 
DRB1*01_f 
CTTGTGGCAGCTTAAGTTTGAAT 
Brilliant® 
55 0.05 
 DRB1*01_r GCATCTTTCCAGCAACCG 
  
C4A C4A_f AGGACCCCTGTCCAGTGTTAGAC ABsolute
™ 
55 0.03 
 C4_r CACTCTCTGCTTCAATGGCT 
   
C4B C4B_f AGGACCTCTCTCCAGTGATACA Brilliant® 57 0.03 
 C4_r CACTCTCTGCTTCAATGGCT 
   
CTins Ctins_f CTCTTCTCCCTGCCTTCCT Brilliant® 57 0.1 
 Ctins_r GCTCTGAGAACCAGTGACTGAGA
G    
Beta-actin Beta-actin_f 
GCACTCTTCCAGCCTTCC 
ABsolute
™ 
60 0.05 
  Beta-actin_r GCGCTCAGGAGGAGCAAT       
HLA-B*35 is first assessed by HLA-B*35_1 qPCR run accompanied by melt-analysis. Positive samples are entered in 
HLA-B*35_2 run, which differentiates real and false positive signals. 
Abbreviations; f forward primer; r, reverse primer. 
 
4.2.1.3. Real-time qPCR 
 
The qPCR method was developed in our Laboratory. Genomic DNA was diluted to 50 
ng/!l in sterile water, and, after assessing purity (A260/A280 >1.7) by spectrophotometer 
(NanoDrop ® ND-1000, NanoDrop Technologies, Wilmington, DE, precision 0.1 ng/!l), 
the sample was adjusted to 10 ng/!l (between 8.0 and 14.0 ng/!l). The primers for C4 
(Sigma Genosys, Heverhill, UK) were selected based on published sequences 181, 193, 197, 
237. Two SYBR® Green Master Mixes (ABsolute™ qPCR SYBR® Green Mix, AB-1159, 
ABgene, Epsom, UK and Brilliant SYBR® Green QPRC Master Mix, Staratagene, AH 
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Diagnostics, Skärholmen, Sweden) with modified Taq polymerase having hot start 
capability were used (Table 19). 
Real-time qPCR was performed with Rotor-Gene 3000 (Qiagen). The qPCR program was 
as follows: Hot start at +95°C for 15 minutes, followed by 30 three-step cycles (15 
seconds at +95°C, 45 seconds at annealing temperature and 45 seconds at +72°C). The 
annealing temperatures were optimized for each run (Table 19). Samples with known C4 
CNV (from 0 to 3 in C4A and C4B runs and from 0 to 1 in CTins run, patient samples 
with consistent immunophenotyping and qPCR results) served as controls. For DRB1*01 
and B*35, controls with 0, 1 and 2 copies were used (III). 
Data were analysed with Rotor-Gene software v 6.0 (Qiagen). The primary data was 
normalized according to the Manufacturer’s instructions. Run validity was ensured by 
controls and adequate standard curves (R2 >0.8). Prior to the C4 CNV analyses, the 
concentration comparability between samples and controls was assured by the 
amplification of a housekeeping gene (beta-actin) in parallel with standard dilutions of 8, 
10 and 14 ng/!l. Samples outside this range were discarded. The sample’s concentration 
was determined as comparable (9–11 ng/!l, assuming control concentration 10 ng/!l), 
lower or higher than the control’s concentration (Figure 14). The threshold level of 
fluorescence was set to separate different CNVs by one threshold cycle (Ct) value. Ct is 
the number of cycles at which the sample’s trace exceeds the arbitrary threshold. Ct 
values >26 were considered as outliers. The use of concentration range was used to 
prevent the false interpretation of CNVs by rounding (Table 20). 
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 Table 20 
Prevention of false interpretation of copy number variation (CNV) by the use of concentration 
range 
Real 
CNV 
False CNV 
interpretation 
X-fold change in the 
amount of DNA 
needed for false 
interpretation 
Concentration for the 
false interpretation 
(ng/ul)a 
Action by beta-
actin runb 
1 2 2.0 20.0 discard 
2 1 0.5 5.0 discard 
3 1.5 15.0 discard 
4 2.0 20.0 discard 
3 1 0.3 3.0 discard 
2 0.6 6.0 discard 
4 1.3 13.0 re-dilute 
4 1 0.25 2.5 discard 
2 0.5 5.0 discard 
3 0.75 7.5 discard 
5 1.25 12.5 re-dilute 
a Result of X-fold change in the sample concentration of 10 ng/ul.  
b Beta-actin inclusion range is 8-14 ng/ul. Samples within this range, but differing from the control's 
concentration are used, but rounded up or down to compensate for the difference. 
 
 
The determination of CNV was performed by visual inspection, superimposing the 
sample’s trace on the controls’ traces. Samples with comparable concentration with the 
controls were recorded as having the CNV of the closest trace (Ct difference <0.4; Figure 
14). Samples with lower or higher concentration than the controls, but within the 
concentration range, were rounded up or down, respectively. The analysis program 
calculates linear standard curve equation, which is formed from controls’ Ct-values and 
logarithmic transformation of a given concentration (with beta-actin analyses) or CNV 
(with C4 analyses). The unknown sample’s DNA quantity is calculated from the equation 
of standard curve with the obtained Ct value. This value was used as a “second opinion”. 
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Figure 14. Sample quality check-up and analysis workflow. The sample validity is first assessed 
by assuring sample purity by spectrophotometer and subsequently in beta-actin run (1). If the 
sample quality is adequate, the sample’s relation to C4 controls is also assessed (2). 
 
 
4.2.1.3 HLA analyses 
 
The presence of B*35 and DRB1*01 was assessed with the qPCR procedure described 
above (III) except for population sample, which was assessed by commercial kit (SSP for 
HLA-B and HLA-DRB, Qiagen; Table 19). HLA-A, HLA-B and HLA-DRB1 genotypes 
were determined by commercial kits, following the Manufacturer’s instructions (II, IV). 
Four lymphotoxin alpha SNPs were assessed by PCR (II, IV). These data on HLA in 
Studies II and IV were available from a previous study by our group 23. All analyses were 
performed at our HLA-Laboratory accredited by European Federation for 
Immunogenetics. 
 
 
4.2.2 SERUM ANALYSES 
 
Carboxypeptidase B (Roche Diagnostics Gmbh, Mannheim, Germany) and 
neuraminidase (Type IV Sigma-Aldrich Chemie Gmbh, Steinheim, Germany) treated 
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serum samples were separated by electrophoresis and subsequently stained with 
polyclonal anti-C4 antibody (DiaSorin Inc., Stillwater, MN) (I, II, IV) according to Sim 
and Cross 232. The number of C4 genes was estimated from the relative intensities of 
protein bands.  
IgA and IgG antibodies to human recombinant HSP60 (Stressgen, Victoria BC, Canada) 
were detected with enzyme-linked immunoassay. The patients’ values had been 
previously published 312. For the Study IV, the results were adjusted to commercially 
available sample (Sandoglobulin; Sandoz, Basel, Switzerland) as 100 EIU. 
Microimmunofluorescence was used to assess the IgA and IgG antibodies against the 
elementary bodies of the Kajaani 6 strain of Cpn. Immune complexes against Cpn were 
recorded with polyethylene glycol precipitation. Dissociated IgG was measured from 
dissociated immune complexes by microimmunofluorescence. The results have been 
previously published 123. Serum C3 and C4 concentrations were measured by 
nephelometry 224. Creatine kinase MB mass, Troponin T (Roche Diagnostics, GmbH 
Mannheim, Germany; immunochemiluminometric, accredited method), propeptide of B-
type N-terminal natriuretic peptide (Roche Diagnotics; immunochemiluminometric 
method), total cholesterol, HDL, triglycerides (Roche Diagnostics; enzymatic, 
[colorimetric for total cholesterol], accredited method) and hsCRP (Orion Diagnostica, 
Espoo, Finland; photometric, immunochemic, accredited method) were measured 
according to the laboratory standards of the accredited Laboratory Services of the 
Hospital District of Helsinki and Uusimaa (HUSLAB, Helsinki, Finland). LDL 
cholesterol was calculated from the Friedewald formula 321.  
 
4.2.3 STATISTICAL ANALYSES 
 
4.2.3.1 General statistical analyses 
 
All statistical analyses were performed with SPSS, version 12.0.1 (II) and 18.0.3 (I, III-
IV; IBM, New York, NY). Univariate analyses were performed with the appropriate 
statistic (Chi-square test, Fisher’s exact test, Student’s t-test and Mann-Whitney U-test). 
The continuous variables that did not follow normal distribution were log-transformed, if 
the transformation resulted in normal distribution. hsCRP values above 10.0 mg/l were 
excluded in order to eliminate acute infectious and inflammatory reactions (III). 
In studies with qPCR typing of C4, CTins was reduced from the total C4A CNV (I, III). 
Complement C4 genes were assessed as the presence of C4A deficiency (<2 copies), C4B 
deficiency (<2 copies) or these combined (<2 copies of either C4A or C4B; I-IV). HLA-
alleles and haplotypes were assessed as population frequencies (number of 
alleles/2*number of patients; III) and as marker positive cases (II-IV). HLA-haplotypes 
with population frequency <5% in all study materials were summed as “else” (III). 
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The continuous variables were used as such and as dichotomized to high and low levels. 
The cut-off values were based on the suggested values, when available (Table 21). 
The association between different genotyping results was assessed with Cohen’s kappa 
(I). Correlation (r2) was measured with parametric or nonparametric methods (IV). ORs 
with their 95%CIs were assessed by Chi-square statistics or by binary logistic regression. 
Multivariate analysis was done using binary logistic (III, IV), or Cox regression (II, IV). 
The multivariate adjustment was made with the statistically important covariates 
identified in the conditional forward modelling that were subsequently assessed with the 
enter-model (III) or with available background characteristics, regardless of their 
statistical effect on the dependent variable (II, IV). Interaction terms were studied (II–IV). 
Kaplan-Meier test was used to analyse recurrent cardiovascular events between different 
patient groups during the follow-up (II, IV). P-value <0.05 was considered statistically 
significant. The p-value was corrected for multiple comparisons in Study IV, but not in 
Study III. Hazard ratios (HR) were assessed by Cox regression (II, IV). 
 
Table 21    
Cut-off values of continuous variables  
 Study Cut-off value Cut-off point and reference 
hsCRP III 3.0 mg/L in women and 2.5 
mg/L in men 
HUSLAB reference value above 
97.5th percentile, based on healthy 
blood donors 
Cpn serology II, IV   
IC  2 Median 322 
IgA  40 4th quartile 322 
IgG  128 4th quartile 322 
HSP60 IV   
IgA cases vs. controls 22.98 and 44.4EIU Tertile 
IgG cases vs. controls 50.33 and 87.85 EIU Tertile 
IgA follow-up 40.57 EIU Median  
IgG follow-up 71.56 EIU Median  
 
 
4.2.3.2 Power calculation 
 
The observed power with !=0.05 for survival with presence of C4 deficiency using cases 
receiving clarithromycin as cases and those receiving placebo as controls was 63% 
(http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize; II). Power calculation 
with !=0.05 was assessed for case-control setting with the following settings; risk allele 
frequency=0.15, prevalence=0.03, OR=2.37, D’=1.0 with DRB1*01 as the risk marker 
(http://pngu.mgh.harvard.edu/~purcell/gpc/; III) 4, 23.  
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4.2.3.3 Haplotype construction (III) 
 
The diploid C4 copy numbers were split into gene frequency data, based on other gene 
markers (Eronen et al, submitted). For gene copy numbers zero, one and three, the 
splitting was straightforwardly done as gene frequencies of 0/0, 0/1 and 2/1, between the 
two chromosomes, respectively. From 394 cases with two C4A genes, all except 46 were 
assessed as equally distributed between the two chromosomes. For C4B, all cases with 
two genes were distributed equally. All cases with four C4A genes were equally 
distributed, whereas no cases with four C4B genes were detected. 
Haplotypes were constructed using a Bayesian algorithm, PHASE (version 2.1) according 
to the Manufacturer’s instructions 323. The estimates of population haplotype frequencies 
were also drawn from PHASE and the 95%CI was assessed as ±1.96 standard error of 
frequency estimate, SE(f). Haplotypes were entered to Arlequin (version 3.5) 324 for 
analyses of linkage disequilibrium, Hardy-Weinberg equilibrium (HWE) and differences 
in haplotype frequencies between populations (exact population differentiation). The tests 
were performed according to the Manufacturer’s instructions. 
 
4.3 ETHICAL CONSIDERATIONS 
 
The patients included in the studies gave an informed patient consent and the study 
protocols were approved by the Ethics Committee, Department of Medicine, Hospital 
District of Helsinki and Uusimaa (II–IV). The Ethics Committee waived the need for 
committee's approval and patient consent for Study I. This study used a patient material 
that was retrospectively and anonymously analysed as frequency data from our 
Diagnostic Laboratory's results without patient identification, any interventions or 
contacts during the study. The results were commanded on clinical grounds from different 
institutions and used to guide patient care as seen suitable by the treating clinician. The 
clinical studies (II–IV) were performed during 1998–2000 and 2004–2005. Therefore no 
clinical trial number exists. 
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5. RESULTS 
5.1 QPCR METHOD  
 
5.1.1 SPECIFICITY  
 
The specificity was assessed by computer search of published genomic sequence and 
ascertained by the melt-analyse of the PCR products (I). The primers did not recognize 
any other identical sequences and no PCR products of similar size, even when primer 
mismatches were allowed, were found. Melt-analyses did not reveal unspecific amplicons 
for C4A or C4B assays, whereas some unspecific amplification was detected for CTins 
assay. The unspecific amplification in CTins run did not exceed the Ct value and thus did 
not result in false positive recording of CTins. Negative controls and empty wells were 
devoid of any recordable PCR products, indicating the absence of primer-dimers and 
contamination.  
 
5.1.2 RELIABILITY 
 
Internal reliability was tested using two different dilutions, five (for internal validation 
samples) or eight (for external validation samples) independent runs and various 
replications within a run (I). The internal (n=7) and external (n=6) validation samples 
showed concordant results in all replications, showing no inter-assay variation between 
different dilutions or different runs. However, as the CNV is manually determined, the 
numerical data on the reliability reflects mainly the quality of sample processing and data 
recording. 
External reliability was evaluated by concordance rate between different methods (I). It 
was high and essentially similar between different methods, ranging from 95.7 to 98.8% 
for C4A analysis and from 97.2 to 100.0% for C4B analysis (Table 22). CTins was not 
validated by an independent analysis. However, the CTins primer sequence is in parallel 
with the recent sequencing results 197, 237 and all four patient samples with two CTins 
copies had no trace of plasma C4A in immunophenotyping.  
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The qPCR method was applied for patients with STEMI (III). The genetic tests showed 
that C4A CNV was not in HWE in patients and in controls, whereas for C4B, HWE was 
not attained in the reference population sample (p=0.002, p<0.001 and p=0.0416, 
respectively). As the most common C4 status is the presence of two C4A and two C4B 
genes and the presence of homozygous deficiency is very rare, the violation of HWE does 
not question the reliability of the results but rather reflects the rarity of the C4A 
deficiency. 
 
 
5.1.3 CTINS IN C4 DEFICIENCY  
 
The described qPCR method was used to assess the presence of CTins, the most common 
mutation leading to C4A silencing 193. Although the frequency of CTins was low (3–6%), 
it resulted in C4A deficiency in 72–80% of its carriers. This corresponds to 18–20% of 
C4A deficiencies and 3–5% of all cases (I, unpublished observation) (Table 23). It is 
presumed that all CTins mutations are present in C4A because the presence of CTins in 
C4B has been reported only rarely 193, 197, 237, 325.  
 
Table 23       
Frequency of CT insertion (CTins) 
 
        
 CTins  CTins leading to C4A deficiency 
 n (%)  n Of CTins Of C4A 
deficiency 
Of all cases 
Recurrent infections (n=1618) 105 (6.4%)  76 72.4% 19.9 % 4.7 % 
STEMI (n=162)a 5 (3.1%)  4 80.0% 18.2 % 2.5 % 
No CAD (n=316)a 15 (4.7%)  12 80.0% 18.2 % 3.8 % 
a Unpublished data       
 
 
Table 22   
Concordance (%) for C4 qPCR   
Method C4A qPCR C4B qPCR 
Immunophenotyping 95.7 (1436/1500) 97.2 (1499/1542) 
TaqMan qPCR 97.9 (47/48) 100 (48/48) 
Southern blot and paralog 
ratio testa 
98.8 (80/81) 100 (81/81) 
a Concordant results from paralog ratio test and Southern blotting. 
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5.2 MHC IN ACS 
 
5.2.1 C4 DEFICIENCY IN ACS 
 
The association between MHC and NSTE-ACS has been published 23. However, this 
study assessed only the MHC haplotypes. When the frequencies of C4 deficiencies in 
patients with NSTE-ACS and controls were compared, no statistically significant 
difference was seen (IV; Table 24). In addition, C4 deficiency (A and B combined or 
alone) was not associated with anamnestic MI, anamnestic coronary intervention or 
cardiovascular end points during the follow-up of patients with NSTE-ACS (II). C4 
deficiency was not associated with STEMI (III; Table 24). 
 
 
Table 24       
C4 deficiency in ACS      
 
STEMI (III) 
 
NSTE–ACS (IV) 
 
C4 
deficiency 
Patients Controls 
 
Patients Controls 
 
n=162 n=316 p= n=144 n=74 p= 
C4A 13.6 (22) 20.7 (66) 0.057 29.2 (42) 25.7 (19) 0.587 
C4B 50.0 (81) 46.4 (148) 0.454 39.6 (57) 28.4 (21) 0.102 
C4A or C4B 61.1 (99) 64.3 (205) 0.498 66.0 (95) 52.7 (39) 0.057 
Data is expressed as % (n). 
 
 
5.2.2 MHC IN STEMI 
 
When patients with STEMI and controls without CAD were compared, the allele 
frequency of DRB1*01 was higher in patients, but statistical significance was not attained 
(22.84%, 74/324 vs. 17.71%, 113/638, respectively; p=0.057; III). However, when 
patients with STEMI were compared with the reference population, the frequency of 
DRB1*01 was significantly increased in STEMI (22.84%, 74/324 vs. 14.77%, 44/298, 
respectively; p=0.010; Table 25). When the STEMI population was pooled with NSTE-
ACS and obstructive CAD from a previous study 23, DRB1*01 was more frequently 
recorded in all patients than in controls (22.0%, 166/754 vs. 15.0%, 166/1108, 
respectively; p<0.001). B*35 was not associated with STEMI (data not shown).  
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Table 25 
     Allele frequency of DRB1*01 in ACS (III) 
Study population Patients Controls Reference 
population 
pa pb 
DRB1*01 
     STEMI 22.84 (74/324) 17.71 (113/638) 14.7 (44/298) 0.057 0.010 
CADc 22.0 (166/754) 15.0 (166/1108) 
 
<0.001 
 DRB1*01-haplotyped 
     STEMI 5.86 (19/324) 2.82 (18/638) 2.68 (8/298) 0.002 0.052 
ACSe 5.34 (28/524) 2.80 (22/786)   0.019   
Data is expressed as % (n[cases]/n[controls]). 
a Patients vs. controls 
b Patients vs. reference population 
c Patients with STEMI, NSTE-ACS and obstructive CAD combined 
d DRB1*01, no C4 deficiency nor HLA-B*35 
e Patients with STEMI and NSTEMI combined 
 
 
5.2.3 MHC HAPLOTYPE IN ACS 
 
Overall, the haplotype frequencies were similar across all three populations (p=0.075). 
However, a haplotype with DRB1*01 with neither C4A/C4B deficiency nor B*35 (the 
1,1,1,0-haplotype, respectively), was more frequent in patients (5.86%, 19/324) than in 
controls (2.82%, 18/638; p=0.020) but the frequency was only borderline higher than in 
the reference population (2.68%, 8/298; p=0.052; III; Table 25). After multivariate 
adjustment, the presence of the 1,1,1,0-haplotype doubled the risk for STEMI, but only 
between cases and controls (11.1%, 18/162 in cases vs. 5.3%, 18/319 in controls, 
OR=2.69, 95%CI=1.21-5.96; p=0.015, adjusted for LDL and HDL).  
When STEMI and NSTEMI 23 patients were combined, the frequency of the 1,1,1,0-
haplotype was higher in patients than in controls (5.34%, 28/524 vs. 2.80%, 22/786; 
p=0.019; III). The baseline characteristics that were associated with the haplotype were 
lack of family history of CAD and presence of arterial hypertension (p=0.007 and 
p=0.012, respectively). Previous MI was twice as common in haplotype carriers, but the 
difference was not statistically significant (p=0.143). Such differences were detected only 
in the STEMI population. 
 
 
5.2.4 DRB1*01 HAPLOTYPE IN MEN  
 
Genders were assessed separately. In males, both DRB1*01 and the 1,1,1,0-haplotype 
were associated with STEMI (III; Table 26). DRB1*01 was more common in STEMI 
than in controls or in the reference population sample (25.00%, 59/236 in patients, 
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17.74%, 83/468 in controls and 10.20%, 10/98 in the reference population; p<0.05 for 
both comparisons). For the 1,1,1,0-haplotype, the results were similar (6.78%, 16/236 in 
patients, 2.35%, 11/468 in controls and 1.02%, 1/98 in reference population; p<0.05 for 
both comparisons). However, the interaction term between gender and the haplotype was 
not significant, and the statistical power in women was too small to exclude the effect of 
the haplotype. The results were similar when previous material was combined. 
 
Table 26 
     DRB1*01 in ACS in males (III) 
Study 
population 
Patients Controls Reference 
population 
pa pb 
DRB1*01 
     STEMI 25.00 (59/236) 17.74 (83/468) 10.20 (10/98) 0.023 0.002 
CAD 22.32 (133/596) 14.71 (125/850) 
 
<0.001 
 DRB1*01-haplotype 
    STEMI 6.78 (16/236) 2.35 (11/468) 1.01 (1/98) 0.004 0.029 
ACS 5.59 (21/376) 2.12 (12/566)   0.005   
Data is expressed as % (n[cases]/n[controls]). 
a Patients vs. controls 
b Patients vs. reference population 
     
 
5.3 MHC IN INFECTION, INFLAMMATION AND AUTOIMMUNITY  
 
5.3.1 ANTIMICROBIAL TREATMENT AND INFECTION  
 
Due to the small number of end points and marker positive cases of DRB1*01 and B*35 
in the NSTE-ACS population 23, the outcome of the clarithromycin trial was reanalysed 
only in relation to the patients’ C4 deficiency status (II). We studied whether C4 
deficiency affects the antimicrobial treatment effect in preventing cardiovascular end 
points in a post hoc analysis 271.  
In cases with C4 deficiency, clarithromycin was associated with lower end point 
frequency (18.8%, 9/48 vs. 40.4%, 19/47 for clarithromycin vs. placebo use, respectively, 
HR=0.34, 95%CI=0.13–0.86; p=0.021; II). The event-free survival was also better 
(Kaplan-Meier log rank test; p=0.015). The clarithromycin treatment was the only 
baseline characteristic that was associated with decreased number of end points (Cox 
regression, HR=0.15, 95%CI=0.041–0.52; p=0.003). In cases without C4 deficiency, no 
treatment effect was seen. However, the interaction term between C4 deficiency and 
clarithromycin was not significant. The power was too low to exclude the advantage of 
clarithromycin in patients without C4 deficiency. Although the beneficial effect seemed 
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to account for the C4B deficiency, due to the small number of patients, the effects of 
different isotype deficiencies (C4A vs. C4B) could not be reliably estimated.  
C4A deficiency was more common in infection prone patients than in general population 
(24%, 381/1618 vs. 16%, 24/149, OR=1.60, 95%CI=1.02–2.52; p=0.039; I). Cpn 
infection markers did not associate with C4, C4A or C4B deficiency or change during 
antimicrobial treatment (II). 
 
5.3.2 HSCRP  
  
In patients with STEMI, hsCRP data were available at a steady state only from 86 
patients and were further selected to values below 10.0 mg/l resulting in available cases in 
50.0% (81/162) in included patients, 88.7% (283/319) in controls and 96.6% (144/149) in 
the reference population (III). The selection of values below 10.0 mg/L excludes cases 
with acute infection or inflammation and is commonly used, but it also reduces the 
amount of available samples. 
The 1,1,1,0-haplotype carriers had higher hsCRP levels than non-carriers in patients 
(median [IQR] 3.37 [5.27] vs. 1.14 [1.65] mg/L; p=0.019) and controls (median [IQR] 
2.90 [3.03] vs. 1.21 [1.73] mg/L; p=0.009; III). In conditional forward binary regression, 
the 1,1,1,0-haplotype was the only factor to associate with elevated hsCRP levels (levels 
in the top 2.5% of a healthy reference sample) in patients (OR=5.16, 95%CI=1.29–20.54; 
p=0.020), whereas in controls the 1,1,1,0-haplotype and body mass index were identified 
as significant factors (body mass index-adjusted OR=4.18, 95%CI=1.42–12.35; p=0.01; 
III). Neither C4 deficiency, DRB1*01 nor B*35 alone were associated with the elevation 
in hsCRP-level (II, III). The numbers in different subgroups became too small to assess 
the effect of 1,1,1,0-haplotype on hsCRP levels in males. 
 
5.3.3 AUTOANTIBODIES  
 
HSP60 IgA antibodies were associated with ACS (see section 5.4). C4 deficiency was 
associated with elevated HSP60 IgA antibodies in patients with STEMI (r2=0.21, 
p=0.011), but not in controls (IV). The HSP60 IgG was not correlated with C4 deficiency. 
DRB1*01 or DRB1*01-B*35-haplotype were not associated with significant alteration in 
HSP60 IgA. 
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5.4 HSP60 AUTOANTIBODIES IN ACS  
 
After establishing the correlation between C4 deficiency and HSP60 IgA, we wanted to 
see whether the HSP60 IgA was significantly associated with NSTE-ACS (IV). 
 
5.4.1 PATIENTS WITH NSTE-ACS   
 
Serum HSP60 IgA level was higher in patients than in controls (median [IQR] 40.56 
[37.96] vs. 19.72 [16.53]; p<0.001; at admission). The results were similar at all four time 
points, also after correcting for multiple comparisons. The ORs for NSTE-ACS increased 
with increasing HSP60 IgA levels (middle vs. low tertile, OR=2.36 95%CI=1.20–4.62; 
p=0.013 and high vs. low tertile, OR=15.32, 95%CI=5.83–40.08; p<0.001). Adjusting for 
possible confounders (age, gender, B*35, DRB1*01, positive Cpn serology) did not 
change the results (data not shown).  
The association between HSP60 IgG levels and NSTE-ACS was not as clear. In only half 
of the four time points, the IgG levels were significantly higher in patients and increasing 
levels did not translate into increased OR. 
 
5.4.2 PATIENTS WITH CARDIOVASCULAR END POINTS 
 
During the follow-up, 31.65% of patients (44/139) had a cardiovascular end point (ACS, 
death, stroke or refractory angina). In the initial study, clarithromycin treatment was 
associated with significant reduction in the number of end points 271. Therefore the 
treatment groups were analyzed separately. In the placebo group, patients with end points 
had higher HSP60 IgA levels at admission (median [IQR] 56.90 [43.18] vs. 37.08 
[26.89], p=0.035). Baseline characteristics or cardiac biomarkers did not differ in patients 
with or without end points. In the clarithromycin group, no differences were found. 
HSP60 IgG was not different in patients with and without end points in either treatment 
group. 
 
5.4.3 PREDICTION OF CARDIOVASCULAR END POINTS 
 
HSP60 IgA was dichotomized according to median for assessing its predictive role on 
recurrent end points. Patients with HSP60 IgA levels above median, belonging to the 
placebo group had the worst event-free survival, when compared to the other groups 
(Kaplan-Meier logrank; p<0.01 for all; Table 25). There was a significant interaction 
between HSP60 IgA level and study treatment on the occurrence of end points (p=0.026). 
In patients on placebo, elevated HSP60 IgA was associated with future end points, 
independently of background risk factors (adjusted HR=3.16, 95%CI=1.35–7.36; 
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p=0.008), whereas clarithromycin was protective only in the elevated HSP60 IgA group 
(HR=0.23, 95%CI=0.09–0.61; p=0.003). Adjustment was performed for age, gender, 
smoking, body-mass index, diabetes mellitus, hypertension and hypercholesterolemia. In 
patients on clarithromycin, HSP60 IgA had no effect of end points. Similarly, in patients 
with low HSP60 IgA, clarithromycin did not prevent end points.  
 
 
Table 25 ! ! !
Recurrent cardiovascular end points, grouped by randomization and HSP60 
IgA levels 
Randomization HSP60 IgA 
End points Kaplan-
Meier p= % (n/n)
a 
Placebo High 55.9 (19/34) Reference 
Placebo Low 26.5 (9/34) 0.006 
Clarithromycin High 17.1 (6/35) 0.001 
Clarithromycin Low 25.0 (9/36) 0.009 
a patients with/without end points. 
 
 
5.4.4 FACTORS AFFECTING HSP60 AUTOANTIBODIES 
 
HSP60 IgA level in samples taken 12 months apart were strongly correlated (r2 =0.66). 
C4 deficiency, IgA antibodies to Cpn (IV) and periodontal pathogens 312 correlated 
weakly with HSP60 IgA. HSP60 IgA levels were not correlated with baseline 
characteristics, cardiac enzymes or serum levels of C4 or C3 except for hypertension, 
which had negative correlation with HSP60 IgA. 
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6. DISCUSSION 
6.1 QPCR METHOD 
6.1.1 VALIDATION AND APPLICABILITY 
 
CNV is an important form of structural variation of the genome. In addition to small 
insertions and deletions (1–50 base pairs) and large chromosomal arrangements (>1 mega 
base pairs), CNV contributes to the structural differences in genomes between 
individuals. Regions that are susceptible to CNV cover all chromosomes, approximately 
12% of the genome, exceeding the area affected by SNPs 326. CNV causes loss or gain of 
genomic sequence, is usually present as segmental duplication that reflects to the diploid 
copy number of the locus. The genes that are subjected to CNV are often involved in 
immune and environmental pathways, suggesting that the CNV might be involved in 
adaptive selection in human populations. Microarrays and sequencing are used for the 
genome-wide detection or discovery of CNVs 327. For validation of a locus-specific CNV, 
different methods are applied 328.  
Low C4 CNV can be transcribed as C4 deficiency (Table 9 on p. 30). C4 deficiency has 
been linked with various inflammatory conditions and the associations are expanding to 
processes that are not classically seen as such, such as autism 166, 207, 208. Many of the disease 
association studies of C4 deficiency have been performed on small sample size and need 
to be replicated in large-scale materials. As GWAS cannot be used for C4 CNV analysis 
186, 197, 199, there is a need for high-throughput genetic analyses for C4 CNV.  
Various methods for analyzing C4 CNV have been developed. Each of these has their its 
advantages and disadvantages (see Section 2.2.5). One of the major advantages of our 
method it the use of qPCR. Real-time qPCR operates in a closed system, which saves 
time and lowers the risk of contamination. In addition, it is extremely sensitive and 
demands only minute amounts of DNA. The disadvantages are the limited amount of 
probes or assessed genes per run 328, whereas in multiple ligation probe analysis 190, 
various different genetic regions can be covered within a single run. Another limitation is 
the extreme sensitivity to small amounts of DNA, which induces high risk of 
contamination. Possibly underlying the sensitivity and the laboriousness of qPCR run 
optimization, Chung et al. reported technical difficulties in setting up a C4 qPCR analysis 
233. The rate of concordance with southern blotting is essentially comparable with paralog 
ratio test 186, qPCR with TaqMan probing 234 and with our method (I). Therefore the 
optimal method for each laboratory depends on the requirements, sample size, knowhow 
and existing hardware, to name a few.  
Previously, two methods using real-time qPCR for C4 CNV typing have been published. 
Both of them use the TaqMan® chemistry, but differ in qPCR program and data analysis 
189, 234. Contrary to these, we have chosen SYBR® Green, the unspecific dye for our C4 
analyses. Compared with TaqMan®, SYBR® Green is less expensive and can be used 
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with all real-time machines. In addition, the imbalances of amplification between 
reference and control gene may subject qPCR to errors in TaqMan®, but in our method, 
the assays are performed in separate runs that are individually optimized for efficiency 
(I). However, the TaqMan® analyses may also be performed in separate runs, whereby 
the advantage of SYBR® Green would be diminished.  
The disadvantage of our method is it’s extreme sensitivity to DNA quality, amount and 
concentration. We experienced difficulties in comparability of samples isolated with 
different methods (I). Further optimization might thus be needed for example differently 
isolated DNA samples. For TaqMan® C4 qPCR assays, these issues have not been 
reported as problematic. In addition, the unspecific detection of any double-stranded 
DNA by SYBR® Green subjects the method to errors in unspecific replication and for 
primer-dimers. Therefore, proper primer design and validation is essential. The use of 
concentration range also means that our method requires three separate runs for C4 CNV 
determination, whereas with TaqMan the analyses can be performed in one 189 or two 234 
runs. Furthermore, the data is manually analyzed, which is laborious compared to 
automated techniques. Finally, the use of a stringent concentration range increases the 
time to sample handling and dilution.  
Recently, a qPCR method with SYBR® Green detection for total C4 CNV was described 
172. However, no primers, qPCR cycling conditions or data assay methods were provided. 
Our method differs from the previous qPCR methods with SYBR® Green labeling in that 
we perform normalization by selecting only samples with comparable concentration for 
analyses. To the best of my knowledge, this has not been described before. The idea itself 
is not new, but it is a simple way of performing absolute quantification of CNV by 
comparing Ct values of known CNV and an unknown sample. The small differences in 
the amount of input DNA are corrected by rounding up or down manually, whereas the 
previous methods rely on mathematical formulae 329, 330. We have applied the described 
method on over 2000 patient and research samples (I, III)144, 147, 201, 206. We are also using 
the same methodology for HLA-allele assays (III). 
The most important limitations in Study I are the lacking confirmatory assay for CTins 
qPCR run (discussed in section 5.1.3) and the use of immunophenotyping as a 
confirmatory method for C4 CNV analysis. Immunophenotyping itself is subjected to 
many errors and the serologic levels of C4 proteins may vary according to increased 
production or increased consumption, in cases of low quality gels and in subjects with 
homozygous C4 allotypes. In addition, the immunophenotyping was performed in our 
Laboratory in parallel with genotyping. Although the two assays are performed 
independently, the result of genotypic assay might have caused the reanalysis of 
phenotypic data in cases with clearly discrepant results more often than in cases with 
concordant results. This might have enhanced the concordance of the two methods. 
However, as the samples were not initially intended for method validation, but for the 
diagnosis of patient samples, it seems unlikely that the results would be greatly biased. In 
addition, the concordance rates between other, independent C4 CNV assays were 
essentially similar. 
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6.1.2. CTINS 
 
Along with the mere copy number count, CNV may be linked with pathologic states 
through the detailed structure of the CNV region. For example mutations may alter the 
function of the remaining or replicated regions 327.  C4 region is an example of the 
importance of mutation detection. Although low CNV of C4 may lead to C4 deficiency 
the silencing mutations may lead to decreased number of functional C4 gene copies (See 
2.2.4.2).  
CTins is the most common mutation leading to C4A silencing 193. We assessed the 
presence of CTins in parallel with C4 CNV analyses by a similar qPCR. In our material, 
CTins was present in 3–6% of the studied patient populations (I, unpublished data). In 
previous studies, CTins has been recorded in 2–6% in general European populations, but 
is only rarely present in the Asian population 190, 191, 199, 237, 331. We found that the carrier 
status of CTins resulted in C4A deficiency in ! of the cases. If CTins had not been 
assessed, the rate of genetically determined C4A deficiency would have been 20% lower 
(I). This corresponds with the majority of previous data, where CTins was shown to 
account for 10–30% of C4A deficiencies in the general population 190, 202, 332. However, in 
a study by Blanchong et al., the frequency of C4A deficiency caused by CTins was only 
5% 180. The most probable explanation for this variation is the frequency of CTins across 
different populations 197.  
The golden standard for assessing phenotypic deficiencies is immunophenotyping, but it 
is subjected to errors. By reducing the amount of CTins copies from the number of 
functional C4A genes, the rate of “phenotypic” C4A deficiencies can be estimated. The 
comparison of phenotypic vs. genetic (or low CNV-attributed) deficiency might robustly 
help to differentiate, whether a disease association would be due to lower phenotypic C4 
level or linkage with the surrounding genes. The lack of CTins assessment in most of the 
genetic C4 disease association studies might cause a significant bias in comparing the 
frequency of C4A deficiency between the old studies with phenotypic data and the more 
recent studies with CNV data. Therefore, discrepancies seen with C4A deficiency should 
be interpreted in keeping the analysis method and the presence of CTins in mind. In 
addition to CTins, other silencing mutations have been characterized. The frequency of 
these mutations is though to be low 164. 
In including CTins in disease studies, it is important to recognize that CTins is strongly 
associated with DRB1*13 197. This allele should be accounted for when assessing the role 
of C4A deficiencies with CTins, especially in cases of positive associations. 
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6.2 MHC IN ACS  
 
6.2.1 C4 DEFICIENCY IN ACS  
 
No association between any C4 deficiency (A or B) and ACS was detected (II–IV). In 
addition, the frequency of CTins was not increased in patients with STEMI (unpublished 
observation). However, the statistical power was not sufficient to detect small differences 
between cases and controls, and thus a possible role of C4 deficiency in ACS cannot be 
excluded based on the present data. For the independent analyses of C4A and C4B 
deficiency the results were similar in ACS (III, IV) but for recurrent cardiovascular 
events, reliable individual analysis of the two isotypes could not be performed due to 
small number of patients (II). In a previous analysis of recurrent cardiovascular events, 
C4A deficiency was associated with recurrent cardiovascular end points with patients in 
NSTE-ACS 224. However, these data were derived from the clinical intervention trial 
(used in Studies II and IV) without taking into account the study randomization and thus 
the results must be interpreted with caution.  
The presented data is supported by earlier, small-scale studies performed in Sweden, 
where no association with MI with any C4 deficiency was seen 215, 217. On the other hand, 
mortality of MI has been shown to be increased in patients with C4B deficiency in 
Icelandic and Hungarian populations 21, 30. A positive association between C4B deficiency 
and MI has been reported with a Hungarian population, but the timing of phenotypic C4 
measurement and the control population selection may have biased the results 21 (see 
section 2.2.4.3). In another Hungarian study, C4A and C4B deficiencies were also 
associated with obstructive CAD, but only C4A deficiency was associated with a history 
of MI 28. These data were derived from patients undergoing GABG and were thus 
selected. In addition to our Study (III), only one study has used genetic analyses 30. 
One possible explanation for the discrepant findings is differences in the frequency of C4 
deficiency. In Hungarian population, the frequency of C4 deficiency is lower than that 
seen in Sweden and Finland. Alternatively, C4 deficiency might be a risk factor for MI in 
Hungarian but not in Scandinavian populations. Another possibility is that the risk of C4 
is mediated only in high-risk groups such as in smokers 29, 30. However, we did not 
identify any significant role of smoking on the association between C4 deficiency and MI 
(unpublished observation). On the other hand, smoking has been described to be 
associated with HLA-DRB1*01, which in turn is associated with C4B deficiency 23.  
The available data does not allow one to conclude the role of C4 deficiency in ACS or 
CAD as no high–powered genetic study with unbiased patient and control selection exists 
and the large-scale GWAS cannot be used to estimate the role of C4 in MI as no tag SNP 
for C4 exists 186. In the future, a follow-up study with genetic C4 analysis is needed to 
identify the role of C4 deficiency in ACS. It would be interesting to perform a GWAS in 
parallel with C4 CNV analysis to see the possible effect of C4 deficiency in relation to 
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other genetic risk factors for MI.  If only patients who have survived ACS are selected, 
the high case mortality of MI might bias the results significantly 333. In addition, if 
patients with ACS are analysed in during follow-up, ischemia-reperfusion damage may 
bias the results. Extensive complement activation is thought to aggravate the ischemia-
reperfusion damage 334, and if C4 deficiency would limit the reperfusion injury, the 
follow-up data might show a “false” beneficial effect of C4 deficiency on outcome. The 
controls might be either cases without ACS or patients with CAD, not developing ACS, 
depending on the presented hypothesis.  
 
6.2.2 DRB1*01 IN ACS 
 
DRB1*01 has been linked with CAD and MI in previous studies 23, 31, 32. In Study III, 
however, the association between DRB1*01 and ACS was not consistent. The frequency 
of DRB1*01 was not significantly different between patients with STEMI and controls 
without significant obstructive CAD. However, DRB1*01 was significantly higher in 
patients with STEMI than in the reference population representing general population and 
when all patients with CAD from the current and a previous study 23 were compared with 
all controls (III). On the other hand, when only male patients were compared, DRB1*01 
was more common in patients than in controls or in the reference population. As the 
power of this study was adequate to detect over two times increased risk of STEMI, the 
lack of association does not exclude an association with lower OR.  
This discrepancy in the comparisons between cases and controls and cases and the 
reference population might be due to the biased selection of controls. All of them were 
not healthy as they all had symptoms of signs for undergoing coronary angiography. 
Some of them had atherosclerotic changes in their arteries (<50% stenosis). These subtle 
atherosclerotic changes might lead to ACS in the future. The absence of significant 
stenosis is not the best way to select a CAD-free control population. More sensitive 
imaging modalities for excluding CAD should have been applied to exclude the presence 
of CAD in the control material. Due to the limited availability of these imaging 
modalities, these were not performed.  
Previous data shows that DRB1*01 is associated with various inflammatory conditions 
and mostly viral infections 144, 145, 147, 149, 150, 153, 157, 159. These studies suggest that 
DRB1*01 or genetic alterations linked to it might be involved in aberrant inflammatory 
processes. 
Our primary data on NSTE-ACS and heart transplantation patients implied that the 
DRB1*01-B*35 haplotype predisposes to NSTE-ACS and obstructive CAD 23. However, 
in the present study, no association with DRB1*01-B*35 haplotype and STEMI was 
found. Instead, the haplotype with DRB1*01 but without B*35 (the 1,1,1,0-halotype) was 
increased in STEMI compared with CAD-free controls (III). On the other hand, the 
difference in the frequency of 1,1,1,0-haplotype was not significant when comparing the 
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reference population and patients with STEMI. Although the CAD-free control 
population was biased, the difference was still significant after accounting for possible 
confounders. Compared with the previous haplotype study, Study III had more patients 
and controls than the NSTE-ACS 23 and importantly, the control material was 
characterized in more detail.  
The haplotypes in both studies were constructed with similar protocols. One explanation 
for the differences in NSTE-ACS and STEMI populations is that the genetic 
pathophysiology might differ between STEMI and NSTE-ACS. STEMI and NSTE-ACS 
do differ in clinical presentation, thrombus appearance, clinical management, patient’s 
characteristics and possibly in pathophysiology 47, 59, 335. Another explanation is that the 
differences in the gene frequency of the background population bias the results. The 
STEMI population and controls were all collected from the capital area. NSTE-ACS 
patients were derived from different parts of Finland, but the controls came from the 
capital area. The geographical differences in the frequency of B*35 are significant within 
Finland 115. The third explanation is that the lower survival in STEMI could result in 
lower frequency of B*35 333. Perhaps correspondingly, the inclusion rate of STEMI was 
also lower than for the NSTE-ACS study. However, as the B*35 frequency was similar in 
patients and controls, strong negative selection of the DRB1*01-B*35 or B*35 seems 
unlikely. 
The most important limitations of Study III were the possible bias in the control 
population selection and the lacking background information in the reference population. 
In addition, the number of females was too low to reliably assess the role of MHC in 
females. Furthermore, the p-value was not corrected for testing multiple haplotypes 
against cases and controls. The results may have thus resulted in chance after performing 
multiple comparisons. To assess the reliability of the haplotype comparisons further, we 
compared the 95%CIs between the populations. No overlap was seen between the patients 
with STEMI and the controls or the reference population. The population frequency 
estimates account for the presence of multiple haplotypes 323. The association between 
hsCRP and the 1,1,1,0-haplotype supports the hypothesis that the observed difference in 
frequencies is a true one (see Section 6.3.2). 
In the future, the allelic variation linking DRB1*01 and CAD should be elucidated, 
preferably with in-depth analysis of the surrounding MHC. If an atherogenic peptide or a 
set of peptides would be identified, the presentation of these might be modifiable 336. 
Based on structure or function, DRB1*01 shares common features with other DRB types. 
The functional grouping of HLA II has been shown to have great overlap in the bound 
peptides 337 and thus, testing for different supergroups in CAD does not seem an 
interesting approach. The “shared epitope” alleles (DRB1*01:01, DRB1*04:01 and 
DRB1*04:04 in Europeans) were not associated with CAD 31. One way to assess the role 
of DRB1*01 would be to test whether the allele groups that have been associated with 
disease conditions or aberrant immune responses might have an association with CAD. 
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The mechanisms how HLA II allelic variation might cause disease are not fully 
understood and due to the tight linkage disequilibrium in the MHC region, the effect of 
surrounding genes is hard to assess. DQA1 or DQB1 alleles have not been associated 
with CAD independently of DRB1*01 31, 32. The effects of HLA II molecules can possibly 
cover a large amount of inflammatory cells and a variety of functions and no single 
mechanism is likely to explain the biological function of DRB1*01 in CAD.  
 
6.3 MECHANISMS LINKING MHC AND ACS 
 
6.3.1 C4 DEFICIENCY AND ANTIMICROBIAL TREATMENT 
 
In previous studies, both partial homozygous and heterozygous C4 deficiency has been 
associated with increased presence of immune complexes, which, in turn have been 
associated with MI and CAD 217, 218, 338, 339. C4 deficiency has also been linked with 
various inflammatory and infectious conditions 191, 199, 201, 210, 211. Increased inflammation 
and infection have been associated with coronary atherosclerosis, although the causality 
remains to be shown 52, 65. Thus, although hypothetical, there is a biologically valid model 
linking C4 deficiency and CAD/ACS.  
The role of C4 deficiency in recurrent infections (I) or Cpn infection (II) could not be 
reliably assessed. This was due to the shortcomings in patient characterization (I) or to 
weak correlation between serology and the presence of Cpn in atheromas 340. However, 
we found that only patients with a C4 deficiency benefitted from clarithromycin 
treatment, also after accounting for possible confounders (II). The results imply that C4 
deficiency subjects its carriers to infectious or pro-inflammatory condition. In such a 
condition, the antimicrobial or anti-inflammatory effect of clarithromycin, or a 
combination of these two, might be beneficial in preventing recurrent cardiovascular 
manifestations 277. The limitations in the antimicrobial study are the small number of 
patients and the lack of complete information on factors that might be associated with 
future end points, for example the GRACE and the TIMI risk scores 34 (II).  
Another possible explanation for the observation is the unequal subgrouping, which 
might cause a selection bias. The initial study showed a beneficial effect of 
clarithromycin treatment in the whole population 271. Consequently, if the size of the 
selected subgroup is large enough, one is bound to have a significant effect of 
clarithromycin. The number of patients with C4 deficiency was almost two times larger 
than that of those without C4 deficiency (95 vs. 49). In addition, the non-significant 
interaction term between C4 deficiency and clarithromycin treatment might reflect 
unequal selection (i.e. lack of real association) or alternatively the small sample size.  
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The observed result may have also been raised by chance, by performing multiple post 
hoc analyses. Study II is the second post hoc study performed on the initial material. The 
first post hoc analysis assessed the role of periodontal infection on the antimicrobial 
response 341. Contrary to expectations, the lack of positive infection markers was 
associated with a beneficial effect of clarithromycin treatment. Interestingly, the number 
of patients without periodontal infection exceeded the number of patients with markers of 
periodontal infection by two. Therefore the unequal subgrouping discussed above may 
have biased the results of the first post hoc analysis as well. Alternatively, the periodontal 
infection exerts too strong an infectious or inflammatory stimuli, where the use of 
clarithromycin is too weak to show any benefit 341. 
 Unfortunately, the number of patients in different subgroups became too small to 
compare the effects of C4 deficiency and periodontal infection on the antimicrobial 
response. However, C4 deficiency has not been reported to be associated with periodontal 
infection and thus the results might be independent of each other 148.  
To the best of my knowledge, this was the first study assessing the possible 
pharmacogenomics factor in secondary prevention of CAD. Our material is one of the 
three small-scale trials with positive findings 262, 267, 271. The first published study showed 
an advantage in cases with elevated Cpn IgG titers 262. One study reported benefit from 
the use of antimicrobial agents in acute MI, but not UAP, independently of bacterial 
infection markers 267. The frequency of C4 deficiency in Finland is higher than in North 
America, where the majority of the large-scale studies have been performed 202, 342. The 
pharmacogenomic effect of C4 deficiency might explain the lack of association in 
secondary antimicrobial prevention studies 274-276. 
The subgroup analyses of previous studies have not consistently identified any population 
benefitting from antimicrobial treatment. Although currently the data shows no benefit of 
secondary antimicrobial trials for treating CAD 274-276 and some have indicated even 
increased mortality 275, no novel trials should be conducted at this point. However, the 
existing large-scale antimicrobial trials could be reanalyzed in relation to C4 status. If our 
results are replicated, the pharmacogenomic effect of C4 deficiency might be helpful in 
directing personalized treatment to patients. 
 
6.3.2 DRB1*01 AND INFLAMMATION 
 
Supporting the importance of the DRB1*01-related 1,1,1,0-haplotype in STEMI, we 
found an association between the haplotype and increased hsCRP levels both in patients 
and in controls (III). DRB1*01 alone did not affect hsCRP levels in these populations. 
DRB1*01 seemed to be more important in male patients, but due to the small amount of 
data, the effect of DRB1*01 on hsCRP in males could not be assessed.  
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This is the first publication demonstrating that there could be an inflammation-related 
mechanisms linking DRB1*01 and ACS. In previous papers, the association with hsCRP 
and DRB1*01 was not tested 23, 31, 32. Hypothetically, the observed data could mean that 
the 1,1,1,0-haplotype predisposes to plaque rupture by increased inflammatory reactions. 
This assumption is based on the data, by which increased serum hsCRP has been 
associated with the plaque type that is considered prone to rupture 65. Plaque rupture has 
also been shown to be more common in patients with STEMI than with NSTE-ACS, 
possibly explaining the lack of association in NSTE-ACS patients 23, 47. However, in 
addition to plaque rupture, also other mechanisms leading to MI have been described. As 
we do not have data on the underlying cause of STEMI  (plaque rupture vs. erosion, 
primary or secondary MI) 33, the theory above has to be approached critically. 
High hsCRP has also been associated with increased risk of MI/CAD. The assessment of 
hsCRP is not routinely recommended, but it may be beneficial for individuals with 
moderate classical risk factors 89, 241, 244, 245. hsCRP levels have been shown to associate 
with various cardiovascular risk factors, dietary patterns and multiple genetic variation. 
These facts render hsCRP a robust measure of inflammation 244, 343. In addition, elevated 
hsCRP is not seen in all patients with MI 240. Based on our current data, it is impossible to 
say, whether the 1,1,1,0-haplotype is linked with STEMI, with underlying CAD or 
whether it results from chance. 
The limitations of Study III are the lacking data on hsCRP from almost half of the 
patients (discussed in Section 5.3.3). In addition, the p-value in the present or previous 
work was not correct for multiple comparisons. However, when the 95%CI of population 
frequency estimates of the 1,1,1,0-haplotype was compared between different 
populations, no overlap was seen. These frequencies were derived from PHASE, which 
accounts for the presence of multiple haplotypes 323. As we did not have information of 
the genetic variation of CRP-related genes and lifestyle factors, the true effect of the 
1,1,1,0-haplotype on hsCRP levels remains unknown. Larger materials, with data 
available on multiple inflammatory markers and genetic variation of CRP and 
surrounding MHC are warranted to confirm this finding. 
Taken together, the available data shows than DRB1*01 is associated with CAD. The new 
data presented in the Thesis could mean that DRB1*01 might harbor a subtype, defined 
by the surrounding MHC genes, that is associated with increased inflammation and with 
ACS. Based on the current data, the relative importance of DRB1*01 vs. 1,1,1,0-
haplotype cannot be reliably estimated.  
Besides the presented peptides, DRB1*01 might be pathogenic by surface expression 
level. The surface expression level of DRB1*01 is not known, but the transcription level 
is believed to be low 128. Assuming that DRB1*01 has a biological effect, it would be 
interesting to see whether the conditioning on factors affecting its expression, such as 
statin, vitamin D, estrogen and various cytokines would affect the association between 
DRB1*01 and CAD/ACS. The frequency of the 1,1,1,0-haplotype was too low to perform 
such calculations, but interestingly, no association with STEMI was seen in women (III). 
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One could speculate that estrogen, a known suppressor for HLA II expression 128, 344, 
exerts cardioprotection by lowering the expression of a proatherogenic HLA-molecule. 
This might also explain the lack of association with the 1,1,1,0-haplotype and hsCRP 
levels in the population sample as well as the lack of significance in population 
frequencies of 1,1,1,0-haplotype comparing patients with STEMI and reference 
population, which included an increased frequency of premenopausal women. The small 
number of included females prevents drawing any conclusions. 
 
6.3.3 C4 DEFICIENCY AND AUTOIMMUNITY TO HSP60 
 
C4 deficiency was associated with increased IgA autoantibody to HSP60 (IV). HSP60 
IgA, in turn, was associated with ACS and had a significant interaction with 
clarithromycin treatment (discussed in Section 6.4). On the other hand, no association 
between C4 deficiency and hsCRP (II, III) or Cpn infection serology status (II) was 
detected. These data are not sufficient to exclude the association between C4 deficiency 
and inflammatory or infectious conditions due to the shortcomings in patient 
characterization, lack of association between serological and intracellular Cpn infection 
status (discussed in Section 5.2.3) and the robustness of hsCRP (discussed in Section 
5.3.3) as inflammatory marker.  
The possible mechanisms linking C4 deficiency and elevated IgA levels against HSP60 
are not known. However, it can be hypothesized that C4 deficiency might cause elevation 
in HSP60 antibody levels either through lower phenotypic levels of C4 or by linkage to 
the surrounding HLA genes, which would be the true causative agent. The observed data 
does not support the role of low C4 concentration in associating with IgA levels as no 
correlation with serum C4 and HSP60 IgA was seen.  
C4 deficiency might lead to higher amount of infections. Infections, in turn, could lead to 
increased amount of HSP60 IgA by increasing the amount of cross-reactive antibodies. 
C4 deficiency might also cause deficient immune clearance, which could lead to 
increased amount of human HSP60 and eventually to increased autoantibody formation. 
However, these mechanisms are merely speculative and the association between C4 
deficiency and HSP60 IgA needs first to be replicated. Interestingly, C4 deficiency has 
been associated with conditions having high IgA production such as Henoch–Schönlein 
purpura and IgA nephropathy 211, 345, 346.  
 
6.4 HSP60 IGA AND ACS 
 
In studies assessing antibodies against oxidated LDL, IgG antibodies have been shown to 
be associated with CAD/IHD, whereas IgM antibodies are linked with decreased 
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prevalence of CAD 53. Lack of association between HSP60 IgG and cardiovascular 
disease during follow-up has been reported on a two occasions 304, 305. Our data support 
the observation that IgA and IgG may have different roles in ACS 304. We showed that 
HSP60 IgA, but not IgG, was associated with NSTE-ACS (IV). Even though the number 
of patients in different subgroups were small and the control population lacked 
background information, the association between elevated serum HSP60 IgA and NSTE-
ACS seen when comparing patients and controls could be replicated when comparing 
patients with and without end points. The results were not affected by the assessment of 
HSP60 IgA as a continuous or as a categorized variable or the adjustment for possible 
confounders. Elevated HSP60 IgA was independent of CAD-related genes (DRB1*01 and 
DRB1*01-B*35 haplotype) 23 and risk factors. 
IgA autoantibodies have rarely been assessed in CAD/ACS. There are some previous 
publications reporting associations with IgA and CAD, however. The relative fractions of 
IgA are elevated in CAD-related HSP65 antibodies 292, IgA antibodies to oxidized LDL, 
cardiolipin and B2-microglobulin are associated with CAD/ACS 347, 348 and elevated 
serum IgA antibody level predict future CVD 349.    
IgA antibody has subclass (1 and 2), size (monomeric and polymeric) and biochemical 
(glycosylation) variation. The specific receptor for IgA is FC!Ri (aka. CD89), which is 
expressed on DCs, Kupffer cells, eosinophils, basophils, monocytes, macrophages and 
neutrophils. FC!Ri may elicit either pro- or anti-inflammatory functions depending on 
IgA structure, cytokine milieu, genetic alteration of the IgA receptor and possibly also on 
the level of IgA glycosylation 286, 350.  
The biological effects of HSP60-specific IgA are not known. It would seem that the risk 
attribution of HSP60 IgA is not related to ischemia-reperfusion damage, as the cardiac 
enzymes did not correlate with HSP60 IgA levels. The target of HSP60 IgA is present in 
plasma, on stressed endothelial cells and within the cells of an atheromatous plaque 14. 
The possible effects of HSP60 IgA thus cover a wide range or possible reactions, possibly 
involving various different cell types. 
Besides the mere association with ACS (discussed above), the association of elevated 
HSP60 IgA on secondary cardiovascular disease during follow-up was only seen in 
patients treated with placebo. In patients randomized to receive three months of 
clarithromycin, the end points were independent of HSP60 IgA. The interaction term was 
significant. The clarithromycin treatment seems to be beneficial only in what seemed to 
be high-risk patients (e.g. those with high HSP60 IgA).  
There are at least four possible explanations for the observed results. First, human and 
bacterial HSP60 have been shown to cross-react 14. HSP60 IgA has shown mild-to 
moderate correlation with IgA levels against Cpn and periodontal bacteria 304, 312, 351. The 
elevated levels of HSP60 IgA might thus be a caused by increased amount of infection. In 
this group, clarithromycin might have resulted in beneficial treatment effect by reducing 
the infection burden. However, neither periodontal infection 341 nor positive Cpn serology 
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276 have been shown to associate with beneficial treatment effect of macrolides. In 
addition, the serological markers of Cpn (II) and oral bacteria remained unchanged by 
clarithromycin 312. Macrolides affect a moderately broad range of mostly gram-positive 
bacteria 277 and the beneficial effect of clarithromycin might thus result from reduction of 
various infectious pathogens. Previous data indicates that clarithromycin does not 
decrease the HSP60 IgA level 312. 
HSP60 expression is induced by various CAD-predisposing factors 295. The increased 
amount of autologous HSP60 might in turn lead to increased production of 
autoantibodies. The second explanation is that the elevated HSP60 IgA is a result of a 
pro-inflammatory condition. In this inflammatory state, the anti-inflammatory properties 
of clarithromycin 277 might be beneficial in reducing recurrent cardiovascular end points.  
The third explanation is that HSP60 IgA in itself is pro-inflammatory. The moderate to 
strong correlation of HSP60 IgA across 12 months indicates constant production. The 
constant production could be affected by genetic or environmental factors. However, no 
risk factors for CAD were seen to explain the elevation in HSP60 IgA. Of the genetic 
factors studied, only C4 deficiency, but not DRB1*01 was associated with alteration in 
the HSP60 IgA.  
The fourth explanation is that the results are caused by mere chance. As in any medical 
study, a certain amount of chance is operating. However, the association between HSP60 
IgA and CAD could be replicated in two different settings and after adjusting for 
confounders and multiple comparisons. In contrast to the earlier studies of the same 
material (II), 341, patients and controls were evenly distributed by choosing the median as 
a cut-off point for HSP60 IgA in assessing the future cardiovascular end points. This 
reduced the possibility of selection bias, but not that of chance.  
There is one positive and one negative association study reported for HSP60 IgA and 
CAD. The positive study was a nested case-control study of middle-aged dyslipidemic 
men who developed MI during the follow-up. It showed that levels above median at 
inclusion predicted future CVD 304, especially in conjunction with other risk factors 352. 
The study with no apparent association was a case-control study, in which HSP60 IgA 
was initially associated with obstructive CAD 351, but when patients and MI-free controls 
were compared, no difference was seen 353. 
More studies have to be conducted to replicate the observed results in a larger patient 
material treated with optimal medical treatment. If the association is shown to really exist, 
the epitope specificity, cross-reactivity and biological modifications should be determined 
to assess the potential consequences resulting from elevated HSP60 IgA levels. HSP60 is 
not the only heat shock protein involved in CAD/ACS. It would be interesting to see, how 
the combination of HSP antibody repertoire is linked with CAD/ACS and whether the 
HSP genes or their polymorphism affect these associations.  
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7. SUMMARY AND CONCLUSIONS 
 
The first aim of this Thesis was the validation of a novel qPCR method for C4 
analyses. The results showed that the new concentration range approach and SYBR® 
Green labeling can be used in real-time qPCR analyses for C4 CNV determination 
and mutation detection. In addition, the analysis of patient data showed that the 
assessment of CTins can significantly increase the number of C4A deficiencies and as 
it can be easily assessed, CTins determination should be included in disease 
association studies (I). 
The second aim was to ascertain the role of selected MHC genes and alleles in 
different clinical forms of ACS. We were able to confirm the role of a DRB1*01-
haplotype in STEMI, whereas DRB1*01 alone was associated with STEMI only in 
males (III). Contrary to previous data, no effects of other MHC markers were 
detected. However, due to small sample size and inadequate power, the role of C4 
deficiency could not be reliably excluded (III, IV).  
The third aim was to assess the possible biological mechanisms, through which the 
MHC could be linked with ACS. It was observed that the MHC region could be 
involved in the pathogenesis of ACS/CAD by increasing inflammatory, infectious and 
autoimmune states. This was shown by the association with DRB1*01-haplotype and 
elevated hsCRP levels (III), C4 deficiency and the beneficial effect of antimicrobial 
prevention of ACS (II) and the association between C4 deficiency and elevated levels 
of HSP60 IgA, an autoantibody that was discovered to be linked with ACS (IV).  
In conclusion, the MHC region is associated with ACS and there are possible 
biological mechanisms mediating this association. These findings may be important in 
understanding the pathogenesis of ACS, but larger materials with more in-depth 
genetic analyses are warranted to replicate these findings and to address the possible 
causality. 
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